=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehaf190.pdf",
  "converted_date": "2026-01-31T14:48:50.120672",
  "file_size_bytes": 2226135,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehaf190.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
European Heart Journal (2025) 46, 4359–4378
https://doi.org/10.1093/eurheartj/ehaf190
2025 Focused Update of the 2019 ESC/EAS
Guidelines for the management of
dyslipidaemias
Developed by the task force for the management of dyslipidaemias
of the European Society of Cardiology (ESC) and the European
Atherosclerosis Society (EAS)
Authors/Task Force Members: François Mach *†, (ESC Chairperson)
(Switzerland), Konstantinos C. Koskinas*†, (ESC Chairperson) (Switzerland),
Jeanine E. Roeters van Lennep *†, (EAS Chairperson) (Netherlands),
Lale Tokgözoğlu , (Task Force Co-ordinator) (Türkiye), Lina Badimon (Spain),
Colin Baigent (United Kingdom), Marianne Benn (Denmark),
Christoph J. Binder (Austria), Alberico L. Catapano (Italy),
Guy G. De Backer (Belgium), Victoria Delgado (Spain), Natalia Fabin (Italy),
Brian A. Ference (United Kingdom), Ian M. Graham (Ireland),
Ulf Landmesser (Germany), Ulrich Laufs (Germany), Borislava Mihaylova
(United Kingdom), Børge Grønne Nordestgaard (Denmark),
Dimitrios J. Richter (Greece), Marc S. Sabatine (United States of America),
and ESC/EAS Scientific Document Group
* Corresponding authors: François Mach, Department of Cardiology, Geneva University Hospital, Geneva, Switzerland. Tel: +41 22 372 71 92, Email: francois.mach@hug.ch; Konstantinos
C. Koskinas, Department of Cardiology, Bern University Hospital - INSELSPITAL, University of Bern, Bern, Switzerland. Tel: +41 31 632 50 00, Email: Konstantinos.Koskinas@insel.ch; and
Jeanine Roeters van Lennep, Department of Internal Medicine, Erasmus MC Cardiovascular Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands. Tel: +31 (010) 704 0
704, Email: j.roetersvanlennep@erasmusmc.nl
† The three Chairpersons contributed equally to the document and are joint corresponding authors.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA),
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Basic Cardiovascular Science.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy, Cardiovascular
Surgery, Cellular Biology of the Heart, Coronary Pathophysiology and Microcirculation, Development Anatomy and Pathology, Thrombosis.
Patient Forum
This article is co-published with permission in the European Heart Journal and Atherosclerosis. © The European Society of Cardiology and the European Atherosclerosis Society 2025. All rights
reserved. The articles are identical except for stylistic differences in keeping with each journal’s style. Either citation can be used when citing this article.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 2 ---
4360 E S C G u id e l in e s
Document Reviewers: Christian Eugen Mueller, (ESC Review Co-ordinator) (Switzerland), Heinz Drexel,
(EAS Review Co-ordinator) (Austria), Ana Abreu (Portugal), Marianna Adamo (Italy), Suleman Aktaa
(United Kingdom), Folkert W. Asselbergs (Netherlands), Antonio Baldini (Italy), Giuseppe Boriani (Italy),
Margarita Brida (Croatia), Marianne Brodmann (Austria), Edina Cenko (Italy), Nikolaos Dagres (Germany),
Jörn Dopheide (Switzerland), Christoph Ebenbichler (Austria), Estelle Gandjbakhch (France), Diana A. Gorog
(United Kingdom), Ioanna Gouni-Berthold (Germany), Luigina Guasti (Italy), Bettina Heidecker (Germany),
Borja Ibanez (Spain), Stefan James (Sweden), Peter Juni (United Kingdom), Marta Kałużna-Oleksy (Poland),
Konstantin A. Krychtiuk (Austria), Gregory Y.H. Lip (United Kingdom), Roberto Lorusso (Netherlands),
Felix Mahfoud (Switzerland), Marco Metra (Italy), Inge Moelgaard (Denmark), João Morais (Portugal), Lis Neubeck
(United Kingdom), Steven E. Nissen (United States of America), Elena Osto (Austria/Switzerland),
Klaus G. Parhofer (Germany), Leopoldo Perez De Isla (Spain), Maurizio Pesce (Italy/Saudi Arabia),
Zaneta Petrulioniene (Lithuania), Eva Prescott (Denmark), Ernst Rietzschel (Belgium), Bianca Rocca (Italy),
Jose Fernando Rodriguez Palomares (Spain), Xavier Rossello (Spain), Anna Sannino (Germany), Anne Grete Semb
(Norway), Jolanta M. Siller-Matula (Austria), Thenral Socrates (Switzerland), Felix C. Tanner (Switzerland),
Johann Wojta (Austria), Alberto Zambon (Italy), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of this Focused Update have submitted declarations of interest which
are reported in a supplementary document to the Focused Update. See the European Heart Journal online or
https://www.escardio.org/Guidelinesfor supplementary documents as well as evidence tables.
Disclaimer: The European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS) Focused Update represents the views of
the ESC and the EAS and was produced after careful consideration of the scientific and medical knowledge and the evidence available at the
time of their publication. The ESC and the EAS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between
the ESC/EAS Focused Update and any other official recommendations or guidelines issued by the relevant public health authorities, in
particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EAS Focused
Update fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies; however, the ESC/EAS Focused Update does not override, in any way whatsoever, the individual
responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in
consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor does the ESC/EAS Focused Update
exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued
by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their
respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations
relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists.
The ESC and the EAS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect.
Permissions: The content of this ESC/EAS Focused Update has been published for personal and educational use only. No commercial
use is authorized. No part of the ESC/EAS Focused Update may be translated or reproduced in any form without written permission
from the ESC and the EAS. For permissions please email: journals.permissions@oup.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines • Dyslipidaemia • Lipid-lowering drugs • Low-density lipoproteins • Lipoprotein(a) •
Hypertriglyceridaemia • Cardiovascular risk • Familial hypercholesterolaemia • Acute coronary syndromes
Table of contents 8. Primary prevention in people with human immunodeficiency virus
infection..................................................................................................................... 4372
1. Preamble.............................................................................................................. 4361 9. Patients with cancer at high or very high chemotherapy-related
2. Introduction ....................................................................................................... 4363 cardiovascular toxicity risk................................................................................ 4373
3. Estimation of total cardiovascular risk and implications for 10. Dietary supplements.................................................................................... 4373
dyslipidaemia management ............................................................................... 4363 11. Evidence tables ............................................................................................... 4374
4. New low-density lipoprotein cholesterol-lowering therapies ..... 4367 12. Data availability statement......................................................................... 4374
5. Combination of lipid-lowering therapies during index 13. Author information...................................................................................... 4374
hospitalization for acute coronary syndromes......................................... 4369 14. Appendix........................................................................................................... 4374
6. Lipoprotein(a).................................................................................................... 4370 15. References........................................................................................................ 4375
7. Hypertriglyceridaemia.................................................................................... 4371
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 3 ---
ESC Guidelines 4361
Tables of Recommendations DHA Docosahexaenoic acid
EAS European Atherosclerosis Society
Recommendation Table 1 — Recommendations for cardiovascular EMA European Medicines Agency
risk estimation in persons without known cardiovascular disease EPA Eicosapentaenoic acid
(see also Supplementary data online, Evidence Table 1)..................... 4367 ESC European Society of Cardiology
Recommendation Table 2 — Recommendations for FCS Familial chylomicronaemia syndrome
pharmacological low-density lipoprotein cholesterol lowering (see FDA US Food and Drug Administration
also Supplementary data online, Evidence Table 2)............................... 4369 FH Familial hypercholesterolaemia
Recommendation Table 3 — Recommendations for lipid-lowering HDL High-density lipoprotein cholesterol
therapy in patients with acute coronary syndromes (see also HIV Human immunodeficiency virus
Supplementary data online, Evidence Table 3) ........................................ 4370 HR Hazard ratio
Recommendation Table 4 — Recommendations for measurement of LDL-C Low-density lipoprotein cholesterol
lipoprotein(a) (see also Supplementary data online, Evidence Lp(a) Lipoprotein(a)
Table 4)............................................................................................................................. 4370 LVEF Left ventricular ejection fraction
Recommendation Table 5 — Recommendations for drug treatment mAb Monoclonal antibody
of patients with hypertriglyceridaemia (see also Supplementary data MACE Major adverse cardiovascular event(s)
online, Evidence Table 5)................................................................................... 4372 MI Myocardial infarction
Recommendation Table 6 — Recommendations for statin therapy PCI Percutaneous coronary intervention
in primary prevention for people with human immunodeficiency PCSK9 Proprotein convertase subtilisin/kexin type 9
virus infection (see also Supplementary data online, Evidence PPAR Peroxisome proliferator-activated receptor
Table 6) ..................................................................................................................... 4373 PUFA n-3 polyunsaturated fatty acid
Recommendation Table 7 — Recommendations for statin therapy PWH People with HIV
in patients receiving cancer therapy (see also Supplementary data SCORE2 Systematic Coronary Risk Evaluation 2
online, Evidence Table 7)................................................................................... 4373 SCORE2-OP Systematic Coronary Risk Evaluation 2-Older
Recommendation Table 8 — Recommendations for dietary Persons
supplements (see also Supplementary data online, Evidence TC Total cholesterol
Table 8) ..................................................................................................................... 4374 T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
List of tables ULN Upper limit of normal
Table 1 Classes of recommendations.......................................................... 4362
Table 2 Levels of evidence................................................................................ 4362
Table 3 Cardiovascular risk categories........................................................ 4364 1. Preamble
Table 4 Intervention strategies as a function of total cardiovascular
risk and untreated low-density lipoprotein cholesterol levels .......... 4365 Guidelines evaluate and summarize available evidence with the aim of as-
sisting health professionals in proposing the best diagnostic or therapeutic
approach for an individual patient with a given condition. The European
List of figures
Society of Cardiology (ESC) Guidelines are intended for use by health
Figure 1 Treatment goals for low-density lipoprotein cholesterol professionals but do not override their individual responsibility to make
across categories of total cardiovascular risk ........................................... 4366 appropriate and accurate decisions in consideration of each patient’s
Figure 2 Average reduction in low-density lipoprotein cholesterol health condition and in consultation with the patient or the patient’s care-
levels with different pharmacological therapies with proven giver where appropriate and/or necessary aiming at shared care decisions.
cardiovascular benefits........................................................................................ 4368 It is also the health professional’s responsibility to verify the rules and reg-
Figure 3 Association between Lp(a) levels and lifetime risk of major ulations applicable in each country to drugs and devices at the time of pre-
cardiovascular events .......................................................................................... 4371 scription and to respect the ethical rules of their profession.
The ESC Guidelines represent the official position of the ESC on
Abbreviations and acronyms a given topic. Guideline topics are selected for updating after
annual expert review of new evidence conducted by the ESC Clinical
ACS Acute coronary syndromes Practice Guidelines (CPG) Committee. ESC Policies and Procedures
ALT Alanine aminotransferase for formulating and issuing the ESC Guidelines can be found on the
ApoB Apolipoprotein B ESC website (https://www.escardio.org/Guidelines/Clinical-Practice-
ApoC-III Apolipoprotein C-III Guidelines/Guidelines-development/Writing-ESC-Guidelines).
ART Antiretroviral therapy Interim Focused Updates are created when the publication of new
ASCVD Atherosclerotic cardiovascular disease evidence could influence clinical practice before the next full update
AST Aspartate aminotransferase of a Guideline is published. This Focused Update provides new and re-
AVS Aortic valve stenosis vised recommendations for the 2019 ESC/European Atherosclerosis
CAC Coronary artery calcium Society (EAS) Guidelines for the management of dyslipidaemias. View
CI Confidence interval the full 2019 ESC/EAS Guidelines here: https://doi.org/10.1093/
CT Computed tomography eurheartj/ehz455. This Task Force was selected by the ESC and EAS
CV Cardiovascular to include professionals involved with the medical care of patients
CVD Cardiovascular disease with this pathology as well as methodologists.
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 4 ---
4362 E S C G u id e l in e s
Guidelines Task Forces perform a critical review and evaluation of development and validation of prognostic models. The strength of
the published literature on diagnostic and therapeutic approaches in- each recommendation and the level of evidence supporting it are
cluding assessment of the risk–benefit ratio. Recommendations are weighed and scored according to predefined criteria as outlined in
based on major randomized trials and relevant systematic reviews Tables 1 and 2. Patient-Reported Outcome Measures (PROMs) and
and meta-analyses, when available. Systematic literature searches Patient-Reported Experience Measures (PREMs) are also evaluated
are conducted in cases of controversy or uncertainty to ensure that when available as the basis for recommendations and/or discussion in
all key studies were considered. For recommendations related to these Guidelines.
diagnosis and prognosis, additional types of evidence are included, Evidence tables summarizing key information from relevant studies
such as diagnostic accuracy studies and studies focused on the are generated to facilitate the formulation of recommendations, to
Table 1 Classes of recommendations
(cid:19)(cid:2)(cid:13)(cid:10)(cid:11)(cid:10)(cid:18)(cid:13) (cid:157)(cid:18)(cid:16)(cid:12)(cid:10)(cid:13)(cid:7)(cid:26)(cid:11)(cid:18)(cid:26)(cid:4)(cid:20)(cid:19)
(cid:29)(cid:22)(cid:21)(cid:20)(cid:20)(cid:26)(cid:9)(cid:26) (cid:31)(cid:8)(cid:10)(cid:12)(cid:19)(cid:13)(cid:15)(cid:19)(cid:26)(cid:21)(cid:13)(cid:12)(cid:28)(cid:18)(cid:16)(cid:26)(cid:7)(cid:19)(cid:13)(cid:19)(cid:16)(cid:21)(cid:22)(cid:26)(cid:21)(cid:7)(cid:16)(cid:19)(cid:19)(cid:14)(cid:19)(cid:13)(cid:11) (cid:9)(cid:20)(cid:26)(cid:16)(cid:19)(cid:15)(cid:18)(cid:14)(cid:14)(cid:19)(cid:13)(cid:12)(cid:19)(cid:12)(cid:26)(cid:18)(cid:16)(cid:26)(cid:10)(cid:20)(cid:26)(cid:10)(cid:13)(cid:12)(cid:10)(cid:15)(cid:21)(cid:11)(cid:19)(cid:12)
(cid:11)(cid:6)(cid:21)(cid:11)(cid:26)(cid:21)(cid:26)(cid:7)(cid:10)(cid:8)(cid:19)(cid:13)(cid:26)(cid:11)(cid:16)(cid:19)(cid:21)(cid:11)(cid:14)(cid:19)(cid:13)(cid:11)(cid:26)(cid:18)(cid:16)(cid:26)(cid:5)(cid:16)(cid:18)(cid:15)(cid:19)(cid:12)(cid:4)(cid:16)(cid:19)(cid:26)(cid:10)(cid:20)
(cid:3)(cid:19)(cid:13)(cid:19)(cid:2)(cid:15)(cid:10)(cid:21)(cid:22)(cid:1)(cid:26)(cid:4)(cid:20)(cid:19)(cid:17)(cid:4)(cid:22)(cid:1)(cid:26)(cid:19)(cid:127)(cid:19)(cid:15)(cid:11)(cid:10)(cid:8)(cid:19)(cid:129)(cid:26)
(cid:29)(cid:22)(cid:21)(cid:20)(cid:20)(cid:26)(cid:9)(cid:9)(cid:26) (cid:29)(cid:18)(cid:13)(cid:141)(cid:10)(cid:15)(cid:11)(cid:10)(cid:13)(cid:7)(cid:26)(cid:19)(cid:8)(cid:10)(cid:12)(cid:19)(cid:13)(cid:15)(cid:19)(cid:26)(cid:21)(cid:13)(cid:12)(cid:28)(cid:18)(cid:16)(cid:26)(cid:21)(cid:26)(cid:12)(cid:10)(cid:8)(cid:19)(cid:16)(cid:7)(cid:19)(cid:13)(cid:15)(cid:19)(cid:26)(cid:18)(cid:17)(cid:26)(cid:18)(cid:5)(cid:10)(cid:13)(cid:10)(cid:18)(cid:13)(cid:26)(cid:21)(cid:3)(cid:18)(cid:4)(cid:11)(cid:26)(cid:11)(cid:6)(cid:19)(cid:26)(cid:4)(cid:20)(cid:19)(cid:17)(cid:4)(cid:22)(cid:13)(cid:19)(cid:20)(cid:20)(cid:28)(cid:26)
(cid:19)(cid:143)(cid:15)(cid:21)(cid:15)(cid:144)(cid:26)(cid:18)(cid:17)(cid:26)(cid:11)(cid:6)(cid:19)(cid:26)(cid:7)(cid:10)(cid:8)(cid:19)(cid:13)(cid:26)(cid:11)(cid:16)(cid:19)(cid:21)(cid:11)(cid:14)(cid:19)(cid:13)(cid:11)(cid:26)(cid:18)(cid:16)(cid:26)(cid:5)(cid:16)(cid:18)(cid:15)(cid:19)(cid:12)(cid:4)(cid:16)(cid:19)(cid:129)(cid:26)
(cid:26)(cid:26)(cid:26)(cid:29)(cid:22)(cid:21)(cid:20)(cid:20)(cid:26)(cid:9)(cid:9)(cid:21) (cid:157)(cid:19)(cid:10)(cid:7)(cid:6)(cid:11)(cid:26)(cid:18)(cid:17)(cid:26)(cid:19)(cid:8)(cid:10)(cid:12)(cid:19)(cid:13)(cid:15)(cid:19)(cid:28)(cid:18)(cid:5)(cid:10)(cid:13)(cid:10)(cid:18)(cid:13)(cid:26)(cid:10)(cid:20)(cid:26)(cid:10)(cid:13) (cid:30)(cid:6)(cid:18)(cid:4)(cid:22)(cid:12)(cid:26)(cid:3)(cid:19)(cid:26)(cid:15)(cid:18)(cid:13)(cid:20)(cid:10)(cid:12)(cid:19)(cid:16)(cid:19)(cid:12)
(cid:26)
(cid:17)(cid:21)(cid:8)(cid:18)(cid:4)(cid:16)(cid:26)(cid:18)(cid:17)(cid:26)(cid:4)(cid:20)(cid:19)(cid:17)(cid:4)(cid:22)(cid:13)(cid:19)(cid:20)(cid:20)(cid:28)(cid:19)(cid:143)(cid:15)(cid:21)(cid:15)(cid:144)(cid:129)(cid:26)
(cid:26)(cid:26) (cid:26)(cid:26)(cid:26)(cid:29)(cid:22)(cid:21)(cid:20)(cid:20)(cid:26)(cid:9)(cid:9)(cid:3) (cid:20)(cid:19)(cid:17)(cid:4)(cid:22)(cid:13)(cid:19)(cid:20)(cid:20)(cid:28)(cid:19)(cid:143)(cid:15)(cid:21)(cid:15)(cid:144)(cid:26)(cid:10)(cid:20)(cid:26)(cid:22)(cid:19)(cid:20)(cid:20)(cid:26)€(cid:19)(cid:22)(cid:22) ‚(cid:21)(cid:144)(cid:26)(cid:3)(cid:19)(cid:26)(cid:15)(cid:18)(cid:13)(cid:20)(cid:10)(cid:12)(cid:19)(cid:16)(cid:19)(cid:12)
(cid:19)(cid:20)(cid:11)(cid:21)(cid:3)(cid:22)(cid:10)(cid:20)(cid:6)(cid:19)(cid:12)(cid:26)(cid:3)(cid:144)(cid:26)(cid:19)(cid:8)(cid:10)(cid:12)(cid:19)(cid:13)(cid:15)(cid:19)(cid:28)(cid:18)(cid:5)(cid:10)(cid:13)(cid:10)(cid:18)(cid:13)(cid:129)
(cid:29)(cid:22)(cid:21)(cid:20)(cid:20)(cid:26)(cid:9)(cid:9)(cid:9)(cid:26) (cid:31)(cid:8)(cid:10)(cid:12)(cid:19)(cid:13)(cid:15)(cid:19)(cid:26)(cid:18)(cid:16)(cid:26)(cid:7)(cid:19)(cid:13)(cid:19)(cid:16)(cid:21)(cid:22)(cid:26)(cid:21)(cid:7)(cid:16)(cid:19)(cid:19)(cid:14)(cid:19)(cid:13)(cid:11)(cid:26)(cid:11)(cid:6)(cid:21)(cid:11)(cid:26)(cid:11)(cid:6)(cid:19) (cid:9)(cid:20)(cid:26)(cid:13)(cid:18)(cid:11)(cid:26)(cid:16)(cid:19)(cid:15)(cid:18)(cid:14)(cid:14)(cid:19)(cid:13)(cid:12)(cid:19)(cid:12)
(cid:7)(cid:10)(cid:8)(cid:19)(cid:13)(cid:26)(cid:11)(cid:16)(cid:19)(cid:21)(cid:11)(cid:14)(cid:19)(cid:13)(cid:11)(cid:26)(cid:18)(cid:16)(cid:26)(cid:5)(cid:16)(cid:18)(cid:15)(cid:19)(cid:12)(cid:4)(cid:16)(cid:19)(cid:26)(cid:10)(cid:20)(cid:26)(cid:13)(cid:18)(cid:11)
(cid:4)(cid:20)(cid:19)(cid:17)(cid:4)(cid:22)(cid:28)(cid:19)(cid:127)(cid:19)(cid:15)(cid:11)(cid:10)(cid:8)(cid:19)(cid:1)(cid:26)(cid:21)(cid:13)(cid:12)(cid:26)(cid:10)(cid:13)(cid:26)(cid:20)(cid:18)(cid:14)(cid:19)(cid:26)(cid:15)(cid:21)(cid:20)(cid:19)(cid:20)
(cid:14)(cid:21)(cid:144)(cid:26)(cid:3)(cid:19)(cid:26)(cid:6)(cid:21)(cid:16)(cid:14)(cid:17)(cid:4)(cid:22)(cid:129)(cid:26)
Table 2 Levels of evidence
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:13)(cid:12)(cid:28)(cid:15)(cid:24)(cid:11)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)(cid:9)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:20) (cid:26)(cid:14)(cid:27)(cid:13)(cid:30)(cid:15)(cid:16)(cid:8)(cid:16)(cid:22)(cid:16)(cid:28)(cid:7)(cid:9)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:17)(cid:16)(cid:15)(cid:16)(cid:27)(cid:23)(cid:30)(cid:14)(cid:24)(cid:29)(cid:30)(cid:23)(cid:27)(cid:25)(cid:14)(cid:26)(cid:13)(cid:27)(cid:16)(cid:27)(cid:9)(cid:24)(cid:22)(cid:5)(cid:28)(cid:30)(cid:27)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:21)(cid:28)(cid:24)(cid:22)(cid:24)(cid:21)(cid:16)(cid:28)(cid:27)(cid:15)(cid:14)(cid:24)(cid:16)(cid:28)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:19) (cid:26)(cid:14)(cid:27)(cid:28)(cid:16)(cid:14)(cid:5)(cid:30)(cid:27)(cid:22)(cid:26)(cid:22)(cid:8)(cid:14)(cid:16)(cid:22)(cid:23)(cid:26)(cid:13)(cid:24)(cid:10)(cid:30)(cid:23)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:6)
(cid:31)(cid:30)(cid:29)(cid:30)(cid:28)(cid:27)(cid:26)(cid:25) (cid:18)(cid:26)(cid:22)(cid:9)(cid:30)(cid:22)(cid:9)(cid:12)(cid:9)(cid:27)(cid:26)(cid:25)(cid:27)(cid:26)(cid:11)(cid:24)(cid:22)(cid:24)(cid:26)(cid:22)(cid:27)(cid:26)(cid:25)(cid:27)(cid:15)(cid:4)(cid:30)(cid:27)(cid:30)(cid:3)(cid:11)(cid:30)(cid:14)(cid:15)(cid:9)(cid:27)(cid:16)(cid:22)(cid:23)(cid:2)(cid:26)(cid:14)(cid:27)(cid:9)(cid:13)(cid:16)(cid:28)(cid:28)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)
(cid:30)(cid:29)(cid:24)(cid:23)(cid:30)(cid:22)(cid:21)(cid:30)(cid:27)(cid:18) (cid:14)(cid:30)(cid:15)(cid:14)(cid:26)(cid:9)(cid:11)(cid:30)(cid:21)(cid:15)(cid:24)(cid:29)(cid:30)(cid:27)(cid:9)(cid:15)(cid:12)(cid:23)(cid:24)(cid:30)(cid:9)(cid:1)(cid:27)(cid:14)(cid:30)(cid:5)(cid:24)(cid:9)(cid:15)(cid:14)(cid:24)(cid:30)(cid:9)(cid:6)
(cid:20)(cid:13)(cid:18)(cid:10)(cid:11)(cid:21)(cid:12)(cid:13)(cid:19)(cid:14)(cid:14)(cid:18)(cid:15)(cid:19)(cid:16)(cid:26)(cid:17)(cid:18)(cid:26)(cid:20)(cid:19)(cid:20)(cid:20)(cid:21)(cid:22)(cid:29)
(cid:23)(cid:25)(cid:24)(cid:25)(cid:26)(cid:30)(cid:27)(cid:31)(cid:28)(cid:29)(cid:30)(cid:31)©
(cid:144)(cid:141)(cid:143)(cid:141)(cid:27)(cid:129)(cid:20)(cid:127)(cid:2)(cid:18)(cid:129)(cid:127)©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 5 ---
ESC Guidelines 4363
enhance comprehension of recommendations after publication, and to and Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP)
reinforce transparency in the Guidelines development process. The ta- for estimation of 10 year CV risk;2,3 CLEAR Outcomes [Cholesterol
bles are published in their own section of the Focused Update and ref- Lowering via Bempedoic Acid, an ACL (adenosine triphosphate-citrate
erence specific recommendation tables. lyase)-Inhibiting Regimen];4 ELIPSE HoFH (Evinacumab Lipid Studies in
After an iterative process of deliberations, a first Task Force vote on all Patients with Homozygous Familial Hypercholesterolemia);5APPROACH
recommendations is conducted prior to the initiation of rounds of re- (Reduction of Triglyceride Levels in Familial Chylomicronemia
view. A second Task Force vote on all recommendations is conducted Syndrome);6REPRIEVE (Pitavastatin to Prevent Cardiovascular Disease in
after the final round of review and revision. For each vote, the Task HIV Infection);7 STRENGTH (Long-Term Outcomes Study to Assess
Force follows ESC voting procedures and all recommendations require Statin Residual Risk with Epanova in High Cardiovascular Risk Patients
at least 75% agreement among voting members to be approved. with Hypertriglyceridemia);8 STOP-CA (Atorvastatin for Anthracycline-
Voting restrictions may be applied based on declarations of interests. Associated Cardiac Dysfunction);9 SPORT (Supplements, Placebo, or
The writing and reviewing panels provide declaration of interest forms Rosuvastatin Study);10and OMEMI (Omega-3 Fatty acids in Elderly with
for all relationships that might be perceived as real or potential sources of Myocardial Infarction).11Beside these trials, the Task Force also considered
conflicts of interest. Their declarations of interest are reviewed according and discussed: combination therapy with high-dose statin plus ezetimibe and
to the ESC declaration of interest rules which can be found on the ESC intensification of lipid-lowering therapy during the index hospitalization for
website (http://www.escardio.org/doi) and are compiled in a report pub- patients presenting with acute coronary syndromes (ACS), as well as new
lished in a supplementary document with the Guidelines. Funding for the data on lipoprotein(a) [Lp(a)] as a risk modifier.
development of this ESC/EAS Focused Update was derived entirely from Only results that would lead to new or changed Class I/IIa or Class III
the ESC and EAS with no involvement of the healthcare industry. recommendations were selected for inclusion in Recommendation
The ESC CPG Committee supervises and co-ordinates the prepar- Tables. All new recommendations included in this Focused Update are
ation of new Guidelines and Focused Updates and approves their publi- additive to the recommendations of the 2019 ESC/EAS Guidelines for
cation. In addition to review by the ESC CPG Committee, this ESC/EAS the management of dyslipidaemias, and all changed recommendations
Focused Update underwent multiple rounds of peer review on a dedi- substitute those of the 2019 ESC/EAS Guidelines for the management
cated online review platform. The review was conducted by topic ex- of dyslipidaemias.
perts, including members from ESC National Cardiac Societies and After due deliberation, the Task Force decided to update recom-
from relevant ESC Subspecialty Communities. The Focused Update mendations for the following sections of the 2019 ESC/EAS
Task Force considered all review comments and was required to re- Guidelines for the management of dyslipidaemias:
spond to all those classified as major. After appropriate revisions, the
• Recommendations for CV risk estimation, with implementation of
Task Force and the ESC CPG Committee members and the EAS
the new SCORE2 and SCORE2-OP risk prediction algorithms.
Executive Committee approved the final document for publication in
• Recommendations on low-density lipoprotein cholesterol
the European Heart Journal and in Atherosclerosis.
(LDL-C)-lowering therapies, including two new agents for LDL-C-
Unless otherwise stated, the Focused Update content refers to sex,
lowering treatment (bempedoic acid and evinacumab specifically for
understood as the biological condition of being male or female, defined
patients with homozygous familial hypercholesterolaemia)(FH).
by genes, hormones and sexual organs. Off-label use of medication may
• Recommendations for lipid-lowering therapy during index hospital-
be presented in this Focused Update if a sufficient level of evidence
ization of ACS.
shows that it can be considered medically appropriate for a given con-
• Recommendations on Lp(a).
dition. However, decisions on off-label use must be made by the re-
• Recommendations for drug treatment in patients with
sponsible health professional giving special consideration to ethical
hypertriglyceridaemia.
rules concerning healthcare, the specific situation of the patient, patient
• Recommendations for statin therapy in primary CV disease (CVD)
consent, and country-specific health regulations.
prevention for people with human immunodeficiency virus (HIV)
infection.
2. Introduction
• Recommendations for statin therapy for patients with cancer at high
or very high chemotherapy-related CV toxicity risk.
Since the publication of the 2019 ESC/EAS Guidelines for the
• Recommendations for dietary supplements.
management of dyslipidaemias: lipid modification to reduce cardio-
vascular (CV) risk,1 there have been several randomized controlled
trials that might change patient management ahead of the next sched- 3. Estimation of total
uled full dyslipidaemia Guidelines. This 2025 Focused Update ad-
cardiovascular risk and implications
dresses changes in recommendations for the treatment of
dyslipidaemias based on new evidence published up until 31 March for dyslipidaemia management
2025. All major randomized controlled clinical trials and
meta-analyses published after the publication of the 2019 ESC/EAS Atherosclerosis is caused by the progressive deposition of LDL-C and
Guidelines were presented and discussed in detail before a consensus other apolipoprotein-B (ApoB)-containing lipoproteins within the ar-
was reached about any possible classes of recommendations (see tery wall, which triggers a cascade of inflammatory reactions leading
Table 1) and levels of evidence (see Table 2) to be assigned; these to the formation and progression of atherosclerotic plaque. As more
were then voted upon for inclusion by all Task Force members. atherogenic lipoproteins become accumulated within the arterial wall
Members with declared conflicts of interests in specific topics were over time, the atherosclerotic plaque gradually enlarges and the risk
asked to abstain from voting on those topics. of having an acute atherosclerotic CV event increases. LDL-C is not
The Task Force considered and discussed the following new studies, trials, only a risk factor for atherosclerotic CV disease (ASCVD), but like
and any meta-analyses: Systematic Coronary Risk Evaluation 2 (SCORE2) other ApoB-containing lipoproteins is a direct cause of ASCVD;12
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 6 ---
4364 E S C G u id e l in e s
therefore, lowering plasma LDL-C levels should be the main focus for peripheral arterial territories.16 Therefore, because CVD morbidity
preventing atherosclerotic CV events. (non-fatal MI and non-fatal stroke) combined with CVD mortality bet-
In clinical practice, the concentration of circulating LDL-C that can ter reflects the total burden of ASCVD, and in line with the current
become trapped within the artery wall is estimated by measuring plas- 2021 ESC Guidelines on CVD prevention,17this Focused Update en-
ma levels of LDL-C, which represent the total amount of cholesterol dorses the use of risk scores such as SCORE2 and SCORE2-OP (in-
carried by low-density lipoproteins. The objective of estimating a per- stead of the SCORE algorithm) for estimation of the risk of
son’s risk of having an atherosclerotic CV event is to identify individuals experiencing an MI, ischaemic stroke, or fatal atherosclerotic CV event
at elevated risk who may benefit from interventions to lower LDL-C over the next 10 years in persons without known CVD aged between
and other modifiable causes of ASCVD. The clinical benefit of lowering 40 and 89 years (Recommendation Table 1).
LDL-C depends on the achieved LDL-C reduction; therefore, indivi- While calculation of the SCORE was based on each person’s total
duals with higher CV risk require more intense LDL-C lowering to cholesterol level, non-high-density lipoprotein (HDL)-cholesterol
achieve the same absolute level of residual CV risk while on treatment (which is calculated as total cholesterol minus HDL-C) is used as an
as compared with individuals with lower risk. For example, assuming an input in the SCORE2 and SCORE2-OP risk algorithms. Moreover,
average 20% proportional (relative) reduction in risk per each mmol/L while the SCORE algorithm assessed the 10 year risk of fatal CVD
lower LDL-C,13lowering LDL-C by 1 mmol/L (38.67 mg/dL) would re- in persons aged up to 70 years, the SCORE2/SCORE2-OP algorithms
duce the risk of a person with a 20% absolute risk of having an acute (accessible at http://www.heartscore.org) can estimate 10 year risk for
atherosclerotic CV event to 16% (i.e. a 20% relative but 4% absolute both fatal and non-fatal CV events also for apparently healthy people
risk reduction), whereas it would reduce the risk of a person with a aged ≥70 years (up to 89 years). SCORE2 and SCORE2-OP are cali-
10% absolute risk to 8% (a 20% relative but 2% absolute risk reduction). brated to four clusters of countries (low, moderate, high, and very
This Focused Update continues to endorse the concept supported in high CVD risk) based on national CVD mortality rates;2,3 details and
the 2019 ESC/EAS Guidelines1 that a person’s estimated absolute risk charts for these country clusters are in the 2021 ESC Guidelines
risk of having an acute CV event should be used to guide the intensity on CVD prevention.17
of LDL-C lowering. We also acknowledge that the CV risk reduction Table 3presents the updated definitions for very high, high, moder-
achievable by a similar magnitude of lowering atherogenic lipid levels ap- ate, and low CVD risk, using the SCORE2/SCORE2-OP instead of the
pears to be greater at younger ages.14,15 SCORE algorithm for apparently healthy persons (primary prevention).
Numerous randomized trials have demonstrated that lowering This table is intended to replace Table 4of the 2019 ESC/EAS Guidelines.1
LDL-C reduces the risk of both fatal and non-fatal myocardial infarc- As a general concept, it is estimated that the risk of total CVD events is
tions (MI) and ischaemic strokes13 as well as ischaemic events in 2–3 times higher than the risk of fatal CVD events, although this may
Table 3 Cardiovascular risk categories
Very high risk People with any of the following:
• Documented ASCVD, either clinical or unequivocal on imaging. Documented ASCVD includes previous ACS (MI or unstable angina),
chronic coronary syndromes, coronary revascularization (PCI, CABG, and other arterial revascularization procedures), stroke and TIA, and
peripheral arterial disease. Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical
events, such as significant plaquea on coronary angiography or CT scan or on carotid or femoral ultrasound or markedly elevated CAC score
by CTb
• DM with target organ damage,c or at least three major risk factors, or early onset of T1DM of long duration (>20 years)
• Severe CKD (eGFR <30 mL/min/1.73 m2)
• A calculated SCORE2 or SCORE2-OP ≥20% for 10 year risk of fatal or non-fatal CVD
• FH with ASCVD or with another major risk factor
High risk People with any of the following:
• Markedly elevated single risk factors, in particular TC >8 mmol/L (>310 mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or
BP ≥180/110 mmHg
• Patients with FH without other major risk factors
• Patients with DM without target organ damage,c with DM duration ≥10 years or another additional risk factor
• Moderate CKD (eGFR 30–59 mL/min/1.73 m2)
• A calculated SCORE2 or SCORE2-OP ≥10% and <20% for 10 year risk of fatal or non-fatal CVD
Moderate People with any of the following:
risk • Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors
• Calculated SCORE2 or SCORE2-OP ≥2% and <10% for 10 year risk of fatal or non-fatal CVD
Low risk • Calculated SCORE2 or SCORE2-OP <2% for 10 year risk of fatal or non-fatal CVD
ASCVD, atherosclerotic cardiovascular disease; ACS, acute coronary syndromes; BP, blood pressure; CABG, coronary artery bypass graft surgery; CAC, coronary artery calcium; CKD,
chronic kidney disease; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolaemia;
LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP,
Systematic Coronary Risk Evaluation 2-Older Persons; T1DM, type 1 DM; T2DM, type 2 DM; TC, total cholesterol; TIA, transient ischaemic attack.
aTypically defined by >50% stenosis.
be.g. CAC score >300.
cTarget organ damage is defined as microalbuminuria, retinopathy, or neuropathy.
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 7 ---
ESC Guidelines 4365
Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein chol-
esterol levels
Total CV Untreated LDL-C levels
risk
<1.4 mmol/L 1.4 to 1.8 to 2.6 to 3.0 to ≥4.9 mmol/L
(<55 mg/dL) <1.8 mmol/L (55 <2.6 mmol/L (70 <3.0 mmol/L <4.9 mmol/L (≥190 mg/dL)a
to <70 mg/dL) to <100 mg/dL) (100 to <116 mg/ (116 to <190 mg/
dL) dL
Low Lifestyle advice Lifestyle advice Lifestyle advice Lifestyle advice Lifestyle N/Aa
modification,
consider adding
drug if uncontrolled
Moderate Lifestyle advice Lifestyle advice Lifestyle advice Lifestyle Lifestyle N/Aa
modification, modification,
consider adding consider adding
drug if uncontrolled drug if uncontrolled
High Lifestyle advice Lifestyle advice Lifestyle Lifestyle Lifestyle Lifestyle
modification, modification and modification and modification and
consider adding concomitant drug concomitant drug concomitant drug
drug if uncontrolled intervention intervention intervention
Very high: Lifestyle Lifestyle Lifestyle Lifestyle Lifestyle Lifestyle
primary modification, modification, modification and modification and modification and modification and
prevention consider adding consider adding concomitant drug concomitant drug concomitant drug concomitant drug
drug drug intervention intervention intervention intervention
Very high: Lifestyle Lifestyle Lifestyle Lifestyle Lifestyle Lifestyle
secondary modification and modification and modification and modification and modification and modification and
prevention concomitant drug concomitant drug concomitant drug concomitant drug concomitant drug concomitant drug
intervention intervention intervention intervention intervention intervention
CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; N/A, not applicable.
aIn individuals with untreated LDL-C levels ≥4.9 mmol/L, total CV risk is already at least high (Table 3).
vary considerably according to age and sex. In this Focused Update, a 2×
multiplier was used to convert previous SCORE-based thresholds17into Box 1 Risk modifiers for consideration
the SCORE2- or SCORE2-OP-based thresholds to define different cat- beyond the risk estimation based on the
egories of total CVD risk. Notably, this Task Force continues to emphasize SCORE2 and SCORE2-OP algorithms
that risk is a continuum and cut-off points that are used in any CVD risk
Demographic/clinical conditions model to define different levels of risk are, in part, arbitrary and based on
the risk levels at which benefit is evident in clinical trials. Therefore, the • Family history of premature CVD (men: <55 years; women:
<60 years)
SCORE2- and SCORE2-OP-based thresholds presented in this document
• High-risk ethnicity (e.g. Southern Asian)
(Table 3) reflect this concept.
• Stress symptoms and psychosocial stressors
Because existing population-based CVD risk models are relatively
• Social deprivation
crude tools for individual risk prediction,18attention to additional char- • Obesity
acteristics that are known to increase CV risk is reasonable in order to • Physical inactivity
refine risk assessment, as already discussed in the 2021 ESC Prevention • Chronic immune-mediated/inflammatory disorders
Guidelines.17This is particularly relevant for persons around treatment • Major psychiatric disorders
• History of premature menopause
decision thresholds (Recommendation Table 1). Clinical conditions and
• Pre-eclampsia or other hypertensive disorders of pregnancy
selected biomarkers that can be considered as risk modifiers are sum- • Human immunodeficiency virus infection
marized in Box 1. Their presence may support reclassifying an individual • Obstructive sleep apnoea syndrome
to a higher risk category than would be calculated by the SCORE2 Biomarkers
or SCORE2-OP algorithm, and may thereby guide decisions about
• Persistently elevated hs-CRP (>2 mg/L)
LDL-C goals and lipid-lowering interventions.
• Elevated Lp(a) [>50 mg/dL (>105 nmol/L)].
This Focused Update endorses the Class IIa recommendation of the
2019 ESC/EAS Guidelines1that arterial (carotid and/or femoral) plaque CVD, cardiovascular disease; hs-CRP, high sensitivity C-reactive protein; Lp(a),
burden should be considered as a risk modifier in individuals at low or lipoprotein(a).
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 8 ---
4366 E S C G u id e l in e s
SCORE2/SCORE2-OP <2%
Treatment goal •SCORE2/SCORE2-OP ≥2% and <10%
for LDL-C •Young patients (T1DM <35 years; •SCORE2/SCORE2-OP ≥10% and <20%
T2DM <50 years) with DM duration •Markedly elevated single risk factors, in particular
<10 years without other risk factors TC >8 mmol/L (310 mg/dL) or LDL-C >4.9 mmol/L (190 mg/dL)
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:22)(cid:25)(cid:14) or BP ≥180/110 mmHg
Class IIb (cid:21)(cid:31)(cid:20)(cid:20)(cid:19)(cid:27)(cid:26)(cid:18)(cid:23)(cid:17)(cid:22)(cid:16) (cid:13)(cid:12)(cid:11)(cid:10) • •F MH o w deit rh ao teu Ct o Kt Dh e (er G m Fa Rj o 3r 0 r –i 5sk 9 f mac Lt /o mrs in/1.73 m2)
•DM w/o target organ damage, with DM duration ≥10 years
(cid:31)(cid:15)(cid:29)(cid:19)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:9)(cid:25)(cid:17)(cid:8)(cid:13)(cid:7)(cid:6)(cid:8) or other additional risk factor
Class IIa
(cid:21)(cid:31)(cid:20)(cid:28)(cid:28)(cid:27)(cid:26)(cid:18)(cid:23)(cid:17)(cid:22)(cid:16) (cid:13)(cid:12)(cid:11)(cid:10)
•ASCVD (clinical/imaging)
& ≥50% reduction
•SCORE2/SCORE2-OP ≥20%
from baseline
•FH with ASCVD or with another major risk factor
(cid:31)(cid:20)(cid:29)(cid:5)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:1)(cid:12)(cid:18)(cid:127) •Severe CKD (eGFR <30 mL/min/1.73 m2)
Class I (cid:21)(cid:31)(cid:4)(cid:28)(cid:27)(cid:26)(cid:18)(cid:23)(cid:17)(cid:22)(cid:16) (cid:13)(cid:12)(cid:11)(cid:10) •DM & target organ damage: ≥3 major risk factors;
or early onset of T1DM of long duration (>20 years)
•Patients with ASCVD who experience
recurrent vascular events while taking
Class Ia (cid:31)(cid:20)(cid:29)(cid:3)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:129)(cid:8)(cid:13)(cid:141)(cid:27)(cid:127)(cid:12)(cid:18)(cid:127) maximally tolerated statin-based therapy
(cid:21)(cid:31)(cid:2)(cid:2)(cid:27)(cid:26)(cid:18)(cid:23)(cid:17)(cid:22)(cid:16) (cid:13)(cid:12)(cid:11)(cid:10) •Patients with polyvascular (e.g. coronary
and peripheral) arterial disease
(cid:31)(cid:20)(cid:29)(cid:28)(cid:27)(cid:26)(cid:26)(cid:25)(cid:24)(cid:23)(cid:22) (cid:143)(cid:144)(cid:6)(cid:13)(cid:8)(cid:26)(cid:8)
Class IIb
(cid:21)(cid:31)(cid:3)(cid:28)(cid:27)(cid:26)(cid:18)(cid:23)(cid:17)(cid:22)(cid:16) (cid:13)(cid:12)(cid:11)(cid:10)
a Class IIa for individuals in primary prevention with FH at very high risk CV Risk
Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk. ASCVD, atherosclerotic cardiovas-
cular disease; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FH, familial hyper-
cholesterolaemia; LDL-C, low-density lipoprotein cholesterol; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP, Systematic Coronary
Risk Evaluation 2-Older Persons; T1DM, type 1 DM; T2DM, type 2 DM; TC, total cholesterol.
moderate risk. Recent studies have provided important new evidence a new recommendation that the presence of subclinical atherosclerosis
regarding the clinical risk associated with subclinical atherosclerosis by imaging or increased CAC score, if measured, should be considered
documented on coronary or peripheral arterial imaging in persons as risk modifiers in individuals at moderate risk or individuals around
without clinical ASCVD.19 While there are no randomized trials treatment decision thresholds (Recommendation Table 1). It should be
showing that the use of coronary artery calcium (CAC) to classify noted, however, that statin therapy may lead to a decrease in lipid-rich
CV risk and guide therapeutic management improves CV outcomes, plaque and an increase in calcification, indicating plaque stabilization;29,30
nevertheless consideration of CAC improves both discrimination therefore, CAC score should be interpreted with caution in statin-
and reclassification.20 An elevated CAC score has been associated treated patients.
in a graded fashion with a higher risk of adverse CV events in persons For patients with type 2 diabetes mellitus (T2DM) without ASCVD,
without clinical ASCVD (primary prevention);21–23at markedly ele- the 2023 ESC Guidelines for CVD management in patients with dia-
vated CAC values (e.g. CAC score >300), the risk was similar or betes recommend the use of the SCORE2-Diabetes algorithm to esti-
even higher than the risk of patients with known clinical ASCVD mate 10 year CVD risk.31,32
(secondary prevention).24,25 Conversely, a CAC score of zero has It is important to note that the LDL-C treatment goals (Figure 1) and
been associated with a lower risk of ASCVD events and mortality therapeutic guidance (Table 4) for persons in each risk category have
in persons at low to moderate estimated CV risk.26Consideration not changed from the 2019 ESC/EAS Guidelines.1 The intensity of
of CAC improves the accuracy of predicted CVD risk by means of the recommended LDL-C lowering continues to be determined by a
the SCORE2 algorithm.27While the presence of significant (typical- person’s level of risk. Previous studies indicated potential underestima-
ly, obstructive) plaque on invasive or computed tomography tion of CV risk based on the SCORE2 and SCORE2-OP,18and under-
(CT)-based coronary angiography was defined as a feature of very treatment with lipid-lowering therapy in primary prevention if statins
high CV risk in the 2019 ESC/EAS Guidelines,1 the presence of were to be recommended only for persons at very high risk.33
less advanced coronary atherosclerosis with non-obstructive pla- Importantly, however, as outlined in the 2019 ESC/EAS Guidelines,1
ques was more recently shown to be associated with an increased the recommendation to initiate pharmacological LDL-C-lowering ther-
risk of subsequent MI.28Against this background, while coronary im- apy in primary prevention is not restricted to persons at very high risk,
aging or CAC measurement are not indicated as broad screening but depends on both the estimated CV risk and the baseline (untreat-
tests for the purpose of CV risk estimation, this Focused Update includes ed) LDL-C levels (Table 4). This concept was previously illustrated in
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 9 ---
ESC Guidelines 4367
Table 5 of the 2019 ESC/EAS Guidelines, and is now described (without 4. New low-density lipoprotein
changes vs the 2019 ESC/EAS Guidelines) in Recommendation Table 1.
cholesterol-lowering therapies
We further emphasize that the SCORE2 and SCORE2-OP risk-
estimating algorithms were derived from cohorts of participants
Bempedoic acid is an oral small molecule that inhibits cholesterol syn-
without clinical ASCVD who were not receiving lipid-lowering ther-
thesis by inhibiting the action of ATP-citrate lyase, a cytosolic enzyme
apy. As a result, these algorithms should not be used to estimate risk
upstream of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
among persons with existing ASCVD or among persons currently on
pathway.40 Bempedoic acid is a prodrug and the activating enzyme
lipid-lowering therapy, and they should not be used to ‘re-assess’
(very long-chain acyl-CoA synthetase-1) is not expressed in skeletal
risk using lipid measurements obtained after initiating Guideline-
muscle.41Treatment with bempedoic acid has muscle-related adverse
recommended lipid-lowering therapy.
events similar to placebo.40,42 Bempedoic acid (single dose available,
Finally, this Task Force emphasizes that atherosclerosis is a chronic
180 mg/day) reduces LDL-C levels by approximately 23% as mono-
progressive disease that begins early in life and slowly progresses
therapy, approximately 18% when given on a background of statin ther-
over time, and the cumulative exposure to higher LDL-C levels at
younger ages is associated with a higher ASCVD risk later in life.34 apy,40,42 and by 38% when given in a fixed-dose combination with
ezetimibe.43,44Treatment with bempedoic acid decreased C-reactive
Conversely, exposure to lower levels of atherogenic lipids at younger
ages has the potential to reduce the lifetime risk of developing protein and did not result in increased haemoglobin A1c levels in pa-
CVD35and mitigate further progression of subclinical atherosclerosis.15 tients with normoglycaemia or pre-diabetes.45 Mendelian randomiza-
The discrepancy between our understanding of the biology of how ath- tion studies have demonstrated that a genetic variant mimicking the
erosclerosis develops and the practical consequences of informing effect of ATP-citrate lyase inhibition and lowering plasma LDL-C levels
treatment decisions based on 10 year risk underscores the need to de- by the same mechanism of action is associated with similar reductions in
velop a new generation of risk- and benefit-estimating algorithms. the risk of CVD as statins and other non-statin lipid-lowering drugs with
These algorithms should: (i) accurately estimate the lifetime risk of hav- proven benefit per unit decrease in LDL-C levels.46
ing an acute CV event for all individuals regardless of age, and (ii) pro- The CLEAR Outcomes study was a randomized, double-blind,
vide personalized guidance on the optimal timing and intensity of placebo-controlled study that aimed to determine bempedoic acid’s
LDL-C lowering needed by each person to reduce their remaining life- potential for CV risk reduction in statin-intolerant patients at high
time risk of developing an atherosclerotic CV event. risk of developing major adverse CV events (MACE) during a median
Recommendation Table 1 — Recommendations for cardiovascular risk estimation in persons without known cardio-
vascular disease (see also Supplementary data online, Evidence Table 1)
Recommendations Classa Levelb
SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or BP
I B
disorders for estimation of 10-year fatal and non-fatal CVD risk.2c
SCORE2-OP is recommended in apparently healthy people ≥70 years of age without established ASCVD, DM, CKD, genetic/rare lipid or
I B
BP disorders for estimation of 10-year fatal and non-fatal CVD risk.3c
Presence of subclinical coronary atherosclerosis by imaging or increased CAC score by CT should be considered as risk modifiers in
IIa B
individuals at moderate risk or individuals around treatment decision thresholds to improve risk classification.24,27,28,36d
Risk modifierse should be considered in individuals at moderate risk or individuals around treatment decision thresholds to improve risk
IIa B
classification.17,27,37f
In primary prevention,g pharmacological LDL-C-lowering therapy is recommended in persons:
• at very high risk and LDL-C ≥1.8 mmol/L (70 mg/dL), or I A
• at high risk and LDL-C ≥2.6 mmol/L (100 mg/dL)
despite optimization of non-pharmacological measures, to lower CVD risk.1,13,38,39
In primary prevention,g pharmacological LDL-C-lowering therapy should be considered in persons:
• at very high risk and LDL-C ≥1.4 mmol/L (55 mg/dL) but <1.8 mmol/L (70 mg/dL), or
• at high risk and LDL-C ≥1.8 mmol/L (70 mg/dL) but <2.6 mmol/L (100 mg/dL), or
IIa A
• at moderate risk and LDL-C ≥2.6 mmol(L (100 mg/dL) but <4.9 mmol/L (190 mg/dL), or
• at low risk and LDL-C ≥3.0 mmol/L (116 mg/dL) but <4.9 mmol/L (190 mg/dL)
despite optimization of non-pharmacological measures, to lower CVD risk.1,13,38,39
ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CT, computed tomography; CVD, cardiovascular disease;
DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; SCORE2, Systematic Coronary Risk Evaluation 2; SCORE2-OP, Systematic Coronary Risk Evaluation 2-Older Persons
aClass of recommendation.
bLevel of evidence.
cRevised recommendation replacing the respective recommendation based on SCORE in the 2019 ESC/EAS Guidelines.
dRevised recommendation replacing the recommendation on CAC score for CV risk assessment in the 2019 ESC/EAS Guidelines.
eListed in Box 1.
fNew recommendation.
gPersons without known clinical atherosclerotic cardiovascular disease.
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 10 ---
4368 E S C G u id e l in e s
(cid:4)
(cid:14)
(cid:5)
(cid:22) (cid:12)(cid:13) (cid:14)
(cid:12)(cid:13)(cid:11)(cid:15)(cid:14)
(cid:9)(cid:8)(cid:7)(cid:6)(cid:19)(cid:5)(cid:14) (cid:12)(cid:4) (cid:13)(cid:19)(cid:11)(cid:19)(cid:10)(cid:9)(cid:8)(cid:7) (cid:12)(cid:13)(cid:6) (cid:19)(cid:19)
(cid:11)
0
(cid:31)(cid:30)(cid:29)(cid:28)(cid:27)(cid:26)(cid:25)(cid:28) (cid:18)(cid:24) (cid:23)(cid:23) (cid:17)(cid:22)(cid:25) (cid:16)(cid:24)(cid:28) (cid:23)(cid:22) (cid:22)(cid:21) (cid:25)(cid:23)(cid:25) (cid:28) (cid:13)(cid:20) (cid:22)(cid:19) (cid:12)(cid:21)(cid:21) (cid:23) (cid:13)(cid:25) (cid:25)(cid:26) (cid:20)(cid:25) (cid:19)(cid:23) (cid:21)(cid:25)(cid:26)(cid:25) (cid:15)(cid:23) (cid:14)(cid:22) (cid:13)(cid:12)(cid:13)(cid:19)(cid:11)(cid:19)(cid:15)(cid:14) (cid:18)(cid:23)(cid:17)(cid:16)(cid:24)(cid:23)(cid:22)(cid:25)(cid:28) (cid:18)(cid:22) (cid:23)(cid:21) (cid:17)(cid:23)(cid:25) (cid:16)(cid:24)(cid:20)(cid:19) (cid:23)(cid:21) (cid:22)(cid:25) (cid:25)(cid:26) (cid:28)(cid:25) (cid:18)(cid:23) (cid:22) (cid:23)(cid:22) (cid:21)(cid:19) (cid:17)(cid:23)(cid:25) (cid:16)(cid:11)(cid:19) (cid:24)(cid:20)(cid:19) (cid:23)(cid:13) (cid:21) (cid:22)(cid:25) (cid:25)(cid:26) (cid:28)(cid:25) (cid:10)(cid:23) (cid:22) (cid:9)(cid:22) (cid:21)(cid:19) (cid:23) (cid:8)(cid:25)(cid:11) (cid:7)(cid:19) (cid:20)(cid:19) (cid:6)(cid:15) (cid:19)(cid:21)(cid:25) (cid:5)(cid:26)(cid:25) (cid:10)(cid:14)(cid:23) (cid:9)(cid:4)(cid:22)(cid:19) (cid:8)(cid:11) (cid:7)(cid:19) (cid:6)(cid:13) (cid:19)(cid:5) (cid:10)(cid:14) (cid:9)(cid:4)(cid:19) (cid:8)(cid:11) (cid:7)(cid:19) (cid:6)(cid:13) (cid:19)(cid:12) (cid:5)(cid:13) (cid:14) (cid:18)(cid:23)(cid:4)(cid:19) (cid:17)(cid:11) (cid:16)(cid:19) (cid:24)(cid:23)(cid:13) (cid:22)(cid:12) (cid:25)(cid:13)(cid:19) (cid:28) (cid:18)(cid:22)(cid:11) (cid:23)(cid:19) (cid:21) (cid:17)(cid:23)(cid:15) (cid:25) (cid:16)(cid:14) (cid:24)(cid:20)(cid:19) (cid:23)(cid:21) (cid:22)(cid:25) (cid:25)(cid:26) (cid:28)(cid:25) (cid:18)(cid:23) (cid:22) (cid:23)(cid:22) (cid:21)(cid:19) (cid:17)(cid:23) (cid:19)(cid:19)(cid:25) (cid:19)(cid:16)(cid:11) (cid:19)(cid:19) (cid:24)(cid:20) (cid:19)(cid:19)
(cid:19)(cid:23)
(cid:19)(cid:10) (cid:21) (cid:22)(cid:25) (cid:15)(cid:25)(cid:26) (cid:14)(cid:28)(cid:25) (cid:19)(cid:23) (cid:22) +(cid:22) (cid:21) (cid:19) (cid:23) (cid:10)(cid:25)(cid:11)(cid:19) (cid:20) (cid:9)(cid:19)(cid:13) (cid:8)(cid:21)(cid:25) (cid:7)(cid:26) (cid:6)(cid:25) (cid:19)(cid:23)(cid:22) (cid:5)(cid:19) (cid:14)(cid:11)(cid:19) (cid:4)(cid:13)
-10
-20
~20%
~23%
-30
~30%
-40 ~38%
-50
~50%
-60 ~58%
~60% ~60%
-70
~68%
~70%
-80 ~75%~75%
~80%
-90 ~86%
Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular
benefits. BA, bempedoic acid; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; PCSK9 mAb, proprotein convertase subtilisin/kexin type 9
monoclonal antibody.
of 40.6 month follow-up.4A total of 13 970 patients were randomized, Figure 2summarizes the average percentage reduction in LDL-C levels
with approximately 70% in secondary prevention and 30% in primary with different pharmacological therapies, alone or in combination. It
prevention. Patients taking a small dose of a statin (daily dose of ator- should be kept in mind that there is considerable inter-individual vari-
vastatin <10 mg or equivalent) were allowed and constituted 23% of ability in the LDL-C-lowering response to any given lipid-lowering
the trial population. The time-averaged difference in LDL-C between drug or combination, which necessitates monitoring of the treatment
the bempedoic acid and placebo arms was 0.57 mmol/L (22 mg/dL). effects after initiation or adaptation of any LDL-C-lowering therapy.
Treatment with bempedoic acid reduced the rate of MACE, defined As outlined in the 2019 ESC/EAS Guidelines,1 LDL-C levels should
as a composite of death from CV causes, MI, stroke, or coronary revas- be measured 4 to 6 weeks after initiation or intensification of
cularization, by 13% [hazard ratio (HR), 0.87; 95% confidence interval lipid-lowering therapy.
(CI), 0.79–0.96; P = .004). There was no apparent effect on CV death Inclisiran, a small interfering ribonucleic acid (RNA) molecule that in-
(HR, 1.04; 95% CI, 0.88–1.24). Cardiovascular risk reduction with bem- hibits the synthesis of PCSK9, may represent an alternative approach to
pedoic acid is similar to that achieved with statins for a given absolute PCSK9 mAbs (alirocumab and evolocumab). Inclisiran has been shown
magnitude of LDL-C lowering.47 The rate of myalgia was similar in in phase III trials to lower LDL-C levels by approximately 50%.48Two
the two arms. Treatment with bempedoic acid increased the risk of CV outcome trials with inclisiran [>16 000 patients with CVD
having elevations in hepatic enzymes [>2× upper limit of normal (NCT03705234) and 17 000 patients with established ASCVD
(ULN) for either alanine aminotransferase (ALT) or aspartate amino- (NCT05030428)] are currently ongoing and expected to report their
transferase (AST), 4.5% vs 3.0%], renal impairment (11.5% vs 8.6%), hy- primary outcomes in 2026 and 2027, respectively.
peruricaemia (10.9% vs 5.6%), gout (3.1% vs 2.1%), cholelithiasis (2.2% In patients with homozygous FH, in whom statins and PCSK9 inhibi-
vs 1.2%), increased platelet count (7.2% vs 0.8%), and decreased haem- tors have little efficacy and may not suffice to adequately lower LDL-C
atocrit levels (2.3% vs 0.1%). Because bempedoic acid leads to a small levels,49evinacumab, an mAb against ANGPTL3 (angiopoietin-like 3),
and reversible increase in uric acid, caution is required in patients has shown potential benefits with a reduction of LDL-C close to
with a history of gout, even though gout does not constitute an abso- 50%.5,50,51
lute contraindication to bempedoic acid. Patients who are unable to take statins because of adverse effects re-
New recommendations for the use of bempedoic acid for LDL-C present a challenge in clinical practice. In such cases, the addition of a
lowering [complementing the recommendations for pharmacological non-statin lipid-modifying agent to a maximally tolerated statin is a valu-
LDL-C lowering with statins, ezetimibe, and proprotein convertase able therapeutic option.1New evidence supporting the reduction in the
subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) of the risk of ASCVD events with ezetimibe in the absence of statin therapy
2019 ESC/EAS Guidelines1] are shown in Recommendation Table 2. (although not necessarily due to statin intolerance) in older persons
)%(
noitcuder
C-LDL
egarevA
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 11 ---
ESC Guidelines 4369
aged ≥75 years without history of coronary artery disease was pro- data show a 10% cumulative incidence of a second MI, a stroke, or CV
vided in the randomized, open-label EWTOPIA 75 (Ezetimibe death within the first 100 days after experiencing an MI,61reaching 33%
Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular at 5 years.62Even in an ideal post-ACS scenario, it can take up to 12
Disease in 75 or Older).52As a general concept, this Task Force recom- weeks for patients to receive optimal LDL-C-lowering therapy follow-
mends to add non-statin therapies with proven cardiovascular benefit, ing the current stepwise approach that was recommended in the 2019
such as ezetimibe, a PCSK9 mAb, or bempedoic acid, taken alone or in ESC/EAS Guidelines.1This early post-ACS period corresponds to the
combination, to lower LDL-C if the LDL-C goals are not achieved with most vulnerable phase after a major coronary event. Observational
the maximum tolerated dose of a statin; the choice should be based on data show that Guideline-directed, intensive lipid-lowering therapy is
the magnitude of additional LDL-C lowering needed, patient prefer- infrequently prescribed, with few dose adjustments performed after
ence, treatment availability, and cost. hospital discharge,63and that the majority of patients do not achieve
their goals.17,64,65 The reasons for this are multifactorial and may in-
clude prescription inertia (prescription of lower-intensity statin), sub-
Recommendation Table 2 — Recommendations for
pharmacological low-density lipoprotein cholesterol optimal patient adherence related to side effects of lipid-lowering
lowering (see also Supplementary data online, Evidence therapies or reluctance to being treated with statins,59and delays or
Table 2) losses to follow-up after discharge from index hospitalization.
The IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy
Recommendations Classa Levelb International Trial) study showed that the addition of ezetimibe to statin
therapy (simvastatin 40 mg) within <10 days (median 5 days) after an ACS
Non-statin therapies with proven cardiovascular
event resulted in incremental lowering of LDL-C levels and a modest but
benefit,c taken alone or in combination, are
significant reduction of adverse CV events.66Small studies have recently
recommended for patients who are unable to take
demonstrated that very intensive LDL-C-lowering treatment initiated in
statin therapy to lower LDL-C levels and reduce the I A
the acute phase after ACS is safe, feasible, and effective in getting more
risk of CV events. The choice should be based on the
patients to recommended LDL-C goals.67–69 In addition, recent data
magnitude of additional LDL-C lowering from the HUYGENS70 (High-Resolution Assessment of Coronary
needed.4,53,54
Plaques in a Global Evolocumab Randomized Study) and
Bempedoic acid is recommended in patients who are PACMAN-AMI71 (Effects of the PCSK9 Antibody Alirocumab
unable to take statin therapy to achieve the LDL-C I B on Coronary Atherosclerosis in Patients With Acute Myocardial
goal.4
Infarction) trials reported improvements in coronary plaque size and
The addition of bempedoic acid to the maximally composition in response to acute and very intensive LDL-C reduction
tolerated dose of statin with or without ezetimibe in the vulnerable post-ACS population. A continuous reduction in CV ad-
IIa C
should be considered in patients at high or very high verse events has been described even when LDL-C reduction exceeded
risk in order to achieve the LDL-C goal.42,55 current Guideline-recommended treatment goals.72–74Recent data from
Evinacumab should be considered in patients with the SWEDEHEART (Swedish Web-system for Enhancement and
Development of Evidence-based care in Heart disease Evaluated
homozygous familial hypercholesterolaemia aged 5
According to Recommended Therapies) Registry reported the lowest
years or older who are not at LDL-C goal despite IIa B
risk of CV events in those patients who achieved early and sustained
receiving maximum doses of lipid-lowering therapy
LDL-C lowering to recommended goals after MI. A stepwise approach
to lower LDL-C levels.5,50,51
for LDL-C lowering after MI might therefore result in delayed goal attain-
CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein ment as compared with early intensification of treatment.75,76These data
convertase subtilisin/kexin type 9. support ‘the sooner, the lower, the better’ as a therapeutic strategy for
This table complements the table of recommendations for pharmacological low-density
LDL-C lowering in patients with ACS.58
lipoprotein cholesterol lowering in the 2019 ESC/EAS Guidelines and does not replace it.
aClass of recommendation. As the extent of LDL-C reduction in response to pharmacological in-
bLevel of evidence. terventions is predictable based on baseline LDL-C levels, it is reasonable
cEzetimibe, PCSK9 monoclonal antibodies, bempedoic acid.
to assume that a significant proportion of ACS patients will not achieve
their target goal with high-intensity statin treatment alone, prescribed at
discharge.77Therefore, and in line with the current 2023 ESC Guidelines
5. Combination of lipid-lowering for the management of patients with ACS,58this Task Force proposes a
therapies during index strategy of early, intensive LDL-C lowering to be considered in all pa-
tients with ACS, with immediate initiation of statin therapy and combin-
hospitalization for acute coronary
ation treatment with one or more classes of non-statin therapy with
syndromes proven CV benefit as needed, depending on each patient’s lipid-lowering
therapy prior to the ACS event. The choice of drug for combination
A clear association between intensive lipid-lowering therapies and bet- therapy should be based on the magnitude of additional LDL-C lowering
ter outcomes in patients after ACS was demonstrated two decades required. Several drugs and drug combinations with various efficacies and
ago,56,57supporting ‘the lower the better’ principle for LDL-C reduc- onsets of action are available to enable such a ‘strike early and strong’ ap-
tion in this clinical setting. Lipid-lowering therapy is one of the pillars proach (Figure 2). Recommendation Table 3includes two new recommen-
of the management of these patients, both in the early post-ACS set- dations for this clinical setting, for patients who present either with or
ting58and in the chronic, stabilized period after an ACS.59Patients ex- without pre-existing lipid-lowering therapy at the time of the ACS event.
periencing ACS are at particularly elevated risk of recurrent CV events, Beyond the treatment in the acute ACS phase, LDL-C should be checked
especially within the first year after hospital discharge.60Observational 4 to 6 weeks after initiation or intensification of lipid-lowering therapy,
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 12 ---
4370 E S C G u id e l in e s
and lifelong treatment to lower LDL-C levels to recommended targets is after menopause and a second measurement is reasonable, particularly
strongly recommended.1 if the pre-menopausal levels were borderline.78,91 For Lp(a) measure-
Several ongoing clinical trials, such as EVOLVE-MI (EVOLocumab ment, there is substantial variability among different assays, in part relat-
Very Early After Myocardial Infarction; NCT05284747) and ing to apo(a) structure and variability in Kringle-IV repeats, potentially
AMUNDSEN-real [Evolocumab or normal strategies to reach LDL under- or overestimating Lp(a) levels. Although measurement in molar
objectives in acute myocardial infarction upbound to PCI (percutan- units (nmol/L) is preferred, mass units (mg/dL) can be used for clinical
eous coronary intervention); EUDRACT:20210–005738–0], are in- purposes.
vestigating the potential benefit of introducing evolocumab at the Although Lp(a) has not yet been shown to improve risk prediction
time of the ACS event. The results of these trials are expected in on top of currently recommended scores (SCORE2, SCORE2-OP),
2026–2027. another study testing whether elevated Lp(a) could improve MI risk
prediction beyond conventional risk factors showed that Lp(a) con-
Recommendation Table 3 — Recommendations for centrations >47 mg/dL reclassified 23% of first MI events correctly,
lipid-lowering therapy in patients with acute coronary while no events were reclassified incorrectly, in a cohort of 8720
syndromes (see also Supplementary data online, individuals.84
Evidence Table 3) Whether lowering Lp(a) reduces the risk of ASCVD and AVS pro-
gression has yet to be shown; the extent of Lp(a) lowering required
Recommendations Classa Levelb
for clinical benefit is also not known. In the absence of specific
Intensification of lipid-lowering therapy during the Lp(a)-lowering therapies, early risk factor management and more in-
tensive LDL-C lowering is reasonable, considering both absolute CV
index ACS hospitalization is recommended for
risk and Lp(a) levels.78 An online Lp(a) risk and benefit algorithm
patients who were on any lipid-lowering therapy I C
is available at http://www.eas-society.org/LPA_risk_and_benefit_
before admission in order to further lower LDL-C
algorithm. Although small studies have suggested that statins may
levels.
have a slight Lp(a) increasing effect, individual-level data on partici-
Initiating combination therapy with high-intensity
pants in seven randomized, placebo-controlled, statin outcome
statin plus ezetimibe during index hospitalization for trials found that statins had no effect on Lp(a) concentrations.92
ACS should be considered in patients who were IIa B
Therefore, clinical decision-making should be influenced by the de-
treatment-naïve and are not expected to achieve the
gree of Lp(a) elevation and the patient’s other risk factors, and pa-
LDL-C goal with statin therapy alone.66
tients with high levels of Lp(a) should be strongly encouraged to
This table complements the ESC 2019 ESC/EAS Guidelines table and does not replace it. take or continue to take high-intensity statins if their risk is sufficiently
ACS, acute coronary syndromes; LDL-C, low-density lipoprotein cholesterol. high.93
aClass of recommendation. Currently, there are specific Lp(a)-lowering medications being tested
bLevel of evidence.
in randomized clinical trials. The injectable RNA (either antisense oligo-
nucleotide or small interfering RNA)-based therapies that target apoli-
poprotein(a) production in the hepatocyte lower Lp(a) concentration
6. Lipoprotein(a) by 80%–98%.94–97An oral small molecule inhibitor and a small interfer-
ing RNA that can lower Lp(a) significantly are currently under investi-
Epidemiologic and genetic studies strongly support a likely causal and dir- gation.98–100
ect continuous association between high plasma levels of Lp(a) and high- Recommendation Table 4 includes a new recommendation reflecting
er risk of ASCVD and aortic valve stenosis (AVS).78Emerging data are the increase in CV risk across the spectrum of elevated Lp(a) levels.1It
suggesting that high Lp(a) may confer a higher risk of ASCVD and AVS is reasonable to consider elevated Lp(a) levels >50 mg/dL (≥105 nmol/
per particle or cholesterol content than LDL-C.37,79–84The mechanisms L) (affecting at least 20% of the population)83 in order to refine CV
by which Lp(a) and LDL lead to these increased risks therefore likely dif- risk estimation across the spectrum of CV risk; moreover, this cut-off le-
fer.78 Based on studies from the United Kingdom, Denmark, and the vel should be considered as a risk modifier to potentially reclassify the CV
United States of America, the highest risks were for MI and AVS, less risk category specifically in individuals at moderate risk or individuals close
in peripheral artery disease and heart failure, and the lowest risks were to treatment decision thresholds (see Box 1 and Recommendation
for ischaemic stroke and CV and all-cause mortality.37,78,79,85–90 Risk Table 1).
from high Lp(a) increases slightly at levels of 30 mg/dL (62 nmol/L) to
50 mg/dL (105 nmol/L) and becomes clinically relevant above 50 mg/dL
Recommendation Table 4 — Recommendations for
(105 nmol/L), with higher levels associated with a greater increase in
measurement of lipoprotein(a) (see also Supplementary
CV risk. Lp(a) concentration is predominantly determined by genetics data online, Evidence Table 4)
(>90%), more than any other lipoprotein, and levels vary with ethnicity.83
There is an incremental increase in risk caused by higher Lp(a) levels, and Recommendations Classa Levelb
if Lp(a) level is not considered, risk might be substantially underestimated
(Figure 3).78Lp(a) measurement should be considered at least once in Lp(a) levels above 50 mg/dL (105 nmol/L) should be
every adult’s lifetime,1either at the first lipid profile or at the next one considered in all adults as a CV risk-enhancing factor, IIa B
with higher Lp(a) levels associated with a greater
if lipid profiles have previously been performed. Screening is particularly
relevant in younger patients with FH or premature ASCVD and no other increase in risk.37,101
identifiable risk factors, or a family history of premature ASCVD or high
CV, cardiovascular; Lp(a), lipoprotein(a).
Lp(a) levels, or in individuals at moderate risk or around treatment deci- aClass of recommendation.
sion thresholds to improve risk classification. Lp(a) levels may increase bLevel of evidence.
5202SAE/CSE©
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 13 ---
ESC Guidelines 4371
a
Hazard ratio (95% CI) Percentage of individuals
(cid:26)(cid:28)(cid:30)
4.0
(cid:27)(cid:31)(cid:30)
Lifetime risk for major
3.0
cardiovascular events
(cid:27)(cid:28)(cid:30)
2.5
2.0 (cid:29)(cid:31)(cid:30)
(cid:29)(cid:28)(cid:30)
1.5
(cid:31)(cid:30)
1.0
(cid:28)
nmol/L 0 20 50 100 150 200 250 300 350 400
mg/dL 0 10 24 48 71 95 119 138 161 184
Lipoprotein (a)
Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events. CI, confidence interval; Lp(a), lipoprotein (a). The risk of
major CV events starts to slightly increase in individuals with Lp(a) levels >62 nmol/L (30 mg/dL), and the increase in risk becomes more pronounced in
individuals with Lp(a) levels ≥105 nmol/L (50 mg/dL). The grey lines indicates the smoothed adjusted hazard ratio and 95% confidence interval (left
y-axis) for lifetime risk for major CV events for a given Lp(a) concentration relative to the median Lp(a) in the population (data from the United
Kingdom Biobank, sub-analysis including 415 274 white individuals).78aThe blue line shows the frequency distribution of Lp(a) levels, with respective
percentages indicated in the right y-axis (data from the United Kingdom Biobank including 443 180 individuals without prior atherosclerotic CVD).37
7. Hypertriglyceridaemia recently showed that the selective peroxisome proliferator-activated
receptor (PPAR-a) modulator pemafibrate109did not reduce the risk
Triglyceride levels are associated with CV risk independent of LDL-C of MACE in 10 497 patients with T2DM, mild-to-moderate hypertrigly-
levels.102–104 With respect to pharmacological treatment ceridaemia and low HDL-C levels; notably, pemafibrate increased ApoB
of hypertriglyceridaemia, this Task Force continues to recommend and LDL-C levels in that trial. Overall, in contrast to the robust evidence
statins as the first drug of choice to reduce CVD risk in high-risk of ASCVD risk reduction with LDL-C lowering therapies, the efficacy of
patients.1
triglyceride lowering with fibrates in reducing ASCVD risk has not been
Currently available fibrates (gemfibrozil, fenofibrate, bezafibrate) established. This Focused Update supports the Class IIb recommenda-
have moderate triglyceride-lowering effects.105–107Fenofibrate and be- tions of the 2019 ESC/EAS Guidelines for the use of fenofibrate or be-
zafibrate lead to small decreases in LDL-C, but have not reduced MACE zafibrate.1 Fibrates are not indicated to lower serum cholesterol or
(MI, ischaemic stroke, CV mortality) or total mortality in patients trea- LDL-C levels.110
ted with statins. A reduction in non-fatal MI was only seen in subgroup Regarding n-3 polyunsaturated fatty acids (PUFAs), the STRENGTH
analyses of patients with atherogenic dyslipidaemia (low HDL-C and trial was published following the publication of the 2019 ESC/EAS
high triglycerides) in these trials.105,106In a pre-specified subgroup ana- Guidelines.1 The trial failed to demonstrate benefit of a combined
lysis of the FIELD (Fenofibrate Intervention and Event Lowering eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) prepar-
in Diabetes) trial, fenofibrate was associated with a lower risk of ation in 13 078 patients (70% with diabetes; 56% with established
lower-limb amputations, likely not mediated by lipid-related mechan- ASCVD) in lowering MACE (composite of cardiovascular death, non-
isms.108 The PROMINENT (Pemafibrate to Reduce Cardiovascular fatal MI, non-fatal stroke, coronary revascularization, or unstable angina
OutcoMes by Reducing Triglycerides IN PatiENts With DiabeTes) trial requiring hospitalization).8
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 14 ---
4372 E S C G u id e l in e s
Reasons for the discordant results of the negative STRENGTH trial 8. Primary prevention in people
vs those of the positive REDUCE-IT (Reduction of Cardiovascular
with human immunodeficiency
Events with Icosapent Ethyl–Intervention Trial),111which were pub-
lished 2 years earlier, may be related to differences in the study popu- virus infection
lations, active treatment compounds (mixture of EPA and DHA vs
high-dose icosapent ethyl, i.e. a highly purified EPA ethyl ester, re- People with HIV (PWH) have a two-fold increased risk of ASCVD com-
spectively), or placebo formulation (corn oil vs mineral oil-containing pared with the general population.17,122 Underlying mechanisms in-
placebo, respectively).112–114Proposed mechanisms of action of how clude chronic inflammation, immune activation, dyslipidaemia caused
EPA specifically reduces cardiovascular risk are the distinct effects on by antiretroviral therapy (ART), and traditional CV risk factors.123
lipid oxidation, inflammation, membrane structure/organization, chol- Cardiovascular risk is often underestimated in PWH using conventional
esterol domain formation, and endothelial function.115,116In view of risk prediction tools.124In the 2019 ESC/EAS Guidelines,1the recom-
the newer evidence from the STRENGTH trial, this Focused mendation was that lipid-lowering therapy (mostly statins) should be
Update revised the respective recommendation for PUFAs by expli- considered in HIV patients with dyslipidaemia to achieve the LDL-C
citly stating that high-dose icosapent ethyl (as in the REDUCE-IT trial) goal as defined for high-risk patients (Class IIa, Level C). The recently
should be considered for high-risk or very high-risk patients with ele- published REPRIEVE trial justifies an update in the recommendation
vated triglyceride levels (fasting triglyceride level 135-499 mg/dL for statins in PWH. REPRIEVE was a multicentre, randomized, double-
[1.52-5.63 mmol/L]) despite statin therapy to lower CVD events blind, placebo-controlled trial that enrolled 7769 participants in pri-
(Recommendation Table 5). mary prevention with HIV, aged 40 to 75 years with low-to-moderate
Volanesorsen is an antisense oligonucleotide targeting hepatic apoli- ASCVD risk receiving ART.7Patients were randomized to pitavastatin
poprotein C-III (ApoC-III) messenger RNA that lowers plasma levels of 4 mg once daily or placebo. The primary endpoint was MACE, a com-
ApoC-III, triglycerides, and chylomicrons. In a phase III, double-blind, posite of CV death, MI, hospitalization for unstable angina, stroke, tran-
randomized 52 week trial including 66 patients with familial chylomicro- sient ischaemic attack, peripheral arterial ischaemia, revascularization,
naemia syndrome (FCS) and markedly elevated triglyceride levels or death from an undetermined cause. The trial was stopped prema-
(mean baseline levels 2209 mg/dL [24.96 mmol/L]), volanesorsen was turely for efficacy after a median follow-up of 5.1 years, and showed
shown to lower triglyceride levels by 77% within 3 months; levels a 35% lower incidence of MACE in the pitavastatin vs the placebo
<750 mg/dL (<8.48 mmol/L) were achieved in 77% of volanesorsen- group (HR, 0.65; 95% CI, 0.48–0.90; P = .002). Efficacy was similar
treated patients. Common adverse events include thrombocytopenia for men and women—an important finding as women have a higher
requiring frequent monitoring and injection-site reactions in 60% of risk of HIV-associated ASCVD.125 Of note, rates of muscle-related
the patients treated with volanesorsen.6A meta-analysis of individual symptoms and new-onset diabetes were higher in PWH treated with
patient data from three randomized controlled trials including pa- pitavastatin (2.4% vs 1.3% and 5.3% vs 4.0%, respectively). The 5 year
tients with triglyceride levels >500 mg/dL (>5.65 mmol/L) (n = 207) number needed to treat to prevent one MACE was 106. In the
showed a significant reduction in the risk of acute pancreatitis during REPRIEVE trial, pitavastatin 4 mg daily did not interact with antiretro-
a median follow-up of 8.1 months.117 Volanesorsen has been ap- viral drugs; as co-administration of certain statins and specific antiretro-
proved by the European Medicines Agency (EMA) [but not by the viral drugs may result in significant drug interactions, the choice of statin
US Food and Drug Administration (FDA)] as an adjunct to diet in adult should be based on potential drug interactions.126The new recommen-
patients with genetically confirmed FCS and at high risk for pancrea- dation in this Focused Update for statin therapy in PWH aged ≥40
titis in whom response to diet and triglyceride-lowering therapy has years in primary prevention is included in Recommendation Table 6.
been inadequate. This drug should be considered for patients with Although outcome trials of other lipid-lowering therapies have not
severe hypertriglyceridaemia due to FCS (new recommendation in been performed in PWH, data on LDL-C reduction and tolerability
Recommendation Table 5). are available for ezetimibe and PCSK9 mAbs.
Currently, new triglyceride-lowering medications are being Ezetimibe as monotherapy or in combination with statin therapy re-
tested in randomized clinical trials. Injectable RNA-based therapies duces LDL-C levels in PWH receiving ART to a similar extent as in peo-
(either antisense oligonucleotide or small interfering RNA) targeting ple without HIV and is well tolerated, although available studies are
ApoC-III can lower triglyceride concentrations by up to 80% small.127–129 Regarding PCSK9 inhibitors, a randomized, double-blind
depending on the dose, interval, specific agent, and patient popula- trial including 464 PWH receiving ART (35.6% with documented
tion.118–121 ASCVD) showed that evolocumab reduced LDL-C levels by 56.9%
Recommendation Table 5 — Recommendations for drug treatment of patients with hypertriglyceridaemia (see also
Supplementary data online, Evidence Table 5)
Recommendations Classa Levelb
High-dose icosapent ethyl (2 × 2 g/day) should be considered in combination with a statin in high-risk or very high-risk patients with
IIa B
elevated triglyceride levels (fasting triglyceride level 135–499 mg/dL or 1.52–5.63 mmol/L) to reduce the risk of cardiovascular events.8,111
Volanesorsen (300 mg/week) should be considered in patients with severe hypertriglyceridaemia (>750 mg/dL or >8.5 mmol/L) due to
IIa B
familial chylomicronaemia syndrome, to lower triglyceride levels and reduce the risk of pancreatitis.6,117
aClass of recommendation.
bLevel of evidence.
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 15 ---
ESC Guidelines 4373
compared with placebo and was well tolerated.130As yet no data are Recommendation Table 7 — Recommendations for
available for the efficacy and safety of bempedoic acid or icosapent ethyl statin therapy in patients receiving cancer therapy (see
in PWH. also Supplementary data online, Evidence Table 7)
Recommendation Classa Levelb
Recommendation Table 6 — Recommendations for
statin therapy in primary prevention for people with hu- Statins should be considered in adult patients at high
man immunodeficiency virus infection (see also or very high risk of developing chemotherapy-related
Supplementary data online, Evidence Table 6) cardiovascular toxicityc to reduce the risk of IIa B
anthracycline-induced cardiac dysfunction.9,132–134
Recommendation Classa Levelb
aClass of recommendation.
Statin therapy is recommended for people in primary bLevel of evidence.
prevention aged ≥40 years with HIV, irrespective of cBaseline cardiovascular toxicity risk stratification discussed in detail in the 2022 ESC
estimated cardiovascular risk and LDL-C levels, to Guidelines on cardio-onocology.135
I B
reduce the risk of cardiovascular events; the choice
of statin should be based on potential drug
interactions.7
10. Dietary supplements
HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol.
aClass of recommendation. The role of healthy dietary habits in lowering atherogenic lipid levels
bLevel of evidence. and reducing CV risk is discussed in detail in the 2019 ESC/EAS
Guidelines.1 A healthy diet is generally defined as a dietary pattern
low in saturated fat, with a focus on wholegrain products, vegetables,
9. Patients with cancer at high or fruit, and fish.1With respect to dietary supplements, however, there
has not been compelling evidence that these can reduce CV risk. For
very high chemotherapy-related
red yeast rice preparations, although a clinically relevant hypocholes-
cardiovascular toxicity risk terolaemic effect has been reported with selected (purified, high-
dose) preparations, convincing evidence of a clinical benefit resulting
Anthracycline-based chemotherapy is a key component of several from this treatment is missing. Similarly, there has not been evidence
chemotherapy regimens for many types of cancer (e.g. breast cancer that supplementation with PUFAs can lower LDL-C levels or reduce
or lymphoma). Its use is associated with the development of heart fail- the risk of CV events—with the exception of high-dose, purified ico-
ure in up to 20% of patients within 5 years, depending on the accumu- sapent ethyl used in the context of hypertriglyceridaemia. Along the
lated dose received.131 same lines, the recently published OMEMI trial that tested PUFA
Recently, four randomized trials assessed the cardioprotective role (DHA + EPA) in elderly patients (age 70–82 years) without elevated
of statins in patients with cancer receiving anthracycline-based ther- triglycerides with recent (2–8 weeks) acute MI did not show a reduc-
apy.9,132–134The STOP-CA trial was a multicentre, double-blind, ran- tion in clinical events compared with placebo.11The recent SPORT
domized controlled trial comparing atorvastatin 40 mg daily against trial was a single-centre, randomized, single-blind study in persons
placebo in 300 patients with lymphoma. The primary endpoint, defined without history of ASCVD and an increased 10 year risk of ASCVD.
as the proportion of patients with ≥10% absolute decline in left ven- Participants (n = 199) were randomized to rosuvastatin 5 mg daily,
tricular ejection fraction (LVEF) to a final LVEF value <55% at 12 placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast
months, occurred more frequently in the placebo compared with the rice. At 28 days, LDL-C reduction (the study’s primary endpoint) was
atorvastatin group (22% vs 9%, respectively; P = .002).9Three smaller greater with rosuvastatin than with all supplements or placebo, and
trials yielded mixed results132–134 (see supplementary data online), none of the dietary supplements led to a significant LDL-C reduction
which may be explained by differences in patient populations, CV compared with placebo.10 Phytosterols reduce cholesterol absorp-
risk, sample sizes, outcomes, or follow-up duration. Although the evi- tion in the intestinal lumen and increase cholesterol excretion, and
dence supporting the use of statins as cardioprotective treatment for at doses of up to 2 grams per day they can reduce LDL-C levels by
anthracycline-induced cardiotoxicity is not unequivocal, this Focused approximately 10% without reported adverse events. There are no
Update supports the Class IIa recommendation introduced in the studies showing benefit of phytosterols on CV outcomes.138In June
2022 ESC cardio-onocology Guidelines135for statin treatment in pa- 2022, the European Parliament and the Council prohibited the mar-
tients at high or very high risk of developing cancer therapy-related keting of food supplements containing ≥3 mg/day of monacolins
CV toxicity (new recommendation in Recommendation Table 7). This from red yeast rice. Concretely, this corresponds to a ban on mona-
was based on the net positive results of the largest of these trials colins from red yeast rice at a daily dose of ≥3 mg/day, while lower
(STOP-CA) and two meta-analyses of available randomized trials (in- doses of these supplements are under restrictions (warnings) and
cluding unblinded trials),136,137 in combination with the overall safety European Union scrutiny.139
of statins without reported increase in hepatotoxicity or myopathy in Based on the totality of available evidence and in view of the new
this setting.9,132–134 trials published after 2019,10,11this Focused Update does not support
The effects of non-statin lipid-lowering therapies on LVEF or other the use of dietary supplements or vitamins without documented safety
cardiovascular outcomes in patients receiving cancer therapy have and significant LDL-C-lowering efficacy for lowering the risk of ASCVD
not been tested. (new recommendation in Recommendation Table 8).
5202SAE/CSE©
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 16 ---
4374 E S C G u id e l in e s
Recommendation Table 8 — Recommendations for University of Copenhagen, Copenhagen, Denmark; Dimitrios
dietary supplements (see also Supplementary data J. Richter, Cardiac Department, Euroclinic Hospital, Athens, Greece;
online, Evidence Table 8) Marc S. Sabatine, TIMI Study Group, Division of Cardiovascular
Medicine, Brigham and Women’s Hospital, Boston, MA, United States
Recommendation Classa Levelb
of America and Department of Medicine, Harvard Medical School,
Dietary supplements or vitamins without Boston, MA, United States of America.
documented safety and significant LDL-C-lowering
III B
efficacy are not recommended to lower the risk of 14. Appendix
ASCVD.10,11
ESC/EAS Scientific Document Group
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein Includes Document Reviewers and ESC National Cardiac Societies.
cholesterol.
Document Reviewers: Christian Eugen Mueller (ESC Review
aClass of recommendation.
bLevel of evidence. Co-ordinator) (Switzerland), Heinz Drexel (EAS Review
Co-ordinator) (Austria), Ana Abreu (Portugal), Marianna Adamo
(Italy), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs
11. Evidence tables
(Netherlands), Antonio Baldini (Italy), Giuseppe Boriani (Italy),
Margarita Brida (Croatia), Marianne Brodmann (Austria), Edina
Evidence tablesare available at European Heart Journal online.
Cenko (Italy), Nikolaos Dagres (Germany), Jörn Dopheide
(Switzerland), Christoph Ebenbichler (Austria), Estelle Gandjbakhch
12. Data availability statement (France), Diana A. Gorog (United Kingdom), Ioanna Gouni-Berthold
(Germany), Luigina Guasti (Italy), Bettina Heidecker (Germany), Borja
No new data were generated or analysed in support of this research. Ibanez (Spain), Stefan James (Sweden), Peter Juni (United Kingdom),
Marta Kałużna-Oleksy (Poland), Konstantin A. Krychtiuk (Austria),
13. Author information Gregory Y.H. Lip (United Kingdom), Roberto Lorusso (Netherlands),
Felix Mahfoud (Switzerland), Marco Metra (Italy), Inge Moelgaard
Author/Task Force Member Affiliations: Lale Tokgözoğlu, (Denmark), João Morais (Portugal), Lis Neubeck (United Kingdom),
Cardiology, Hacettepe University, Ankara, Türkiye; Lina Badimon, Steven E. Nissen (United States of America), Elena Osto (Austria/
Cardiovascular Health Sciences, UVIC-UCC, Barcelona, Spain, and Switzerland), Klaus G. Parhofer (Germany), Leopoldo Perez De Isla
Translational and Clinical Research, Foundation for Cardiovascular (Spain), Maurizio Pesce (Italy/Saudi Arabia), Zaneta Petrulioniene
Prevention and Innovation, Barcelona, Spain; Colin Baigent, Nuffield (Lithuania), Eva Prescott (Denmark), Ernst Rietzschel (Belgium),
Department of Population Health, University of Oxford, Oxford, Bianca Rocca (Italy), Jose Fernando Rodriguez Palomares (Spain),
United Kingdom; Marianne Benn, Department of Clinical Xavier Rossello (Spain), Anna Sannino (Germany), Anne Grete
Biochemistry, Copenhagen University Hospital - Rigshospitalet, Semb (Norway), Jolanta M. Siller-Matula (Austria), Thenral Socrates
Copenhagen, Denmark and Institute of Clinical Medicine, Copenhagen (Switzerland), Felix C. Tanner (Switzerland), Johann Wojta (Austria),
University, Copenhagen, Denmark; Christoph J. Binder, Laboratory Alberto Zambon (Italy), and Katja Zeppenfeld (Netherlands).
Medicine, Medical University of Vienna, Vienna, Austria; Alberico Contributor either withdrew or was engaged in only a part of the re-
L. Catapano, Center for the Study of Atherosclerosis, Multimedica view process: Winfried Maerz (Germany)
IRCCS, Milan, Italy and Department of Pharmacological and ESC National Cardiac Societies actively involved in the review
Biomolecular Sciences, University of Milan, Milan, Italy; Guy G. De process of the 2025 Focused Update of the 2019 ESC/EAS Guidelines
Backer, Public Health and Primary Care, Ghent University, Ghent, for the management of dyslipidaemias:
Belgium; Victoria Delgado, Cardiology, Hospital University Germans Algeria: Algerian Society of Cardiology, Nadia Laredj; Armenia:
Trias i Pujol, Badalona, Spain; Natalia Fabin, Department of Armenian Cardiologists Association, Hamlet Hayrapetyan; Austria:
Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy Austrian Society of Cardiology, Walter Stefan Speidl; Azerbaijan:
and Department of Cardiovascular Diseases, IRCCS Humanitas Azerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian
Research Hospital, Rozzano, Milan, Italy; Brian A. Ference, Society of Cardiology, Philippe van de Borne; Bosnia and
Cardiovascular Medicine, Deep Causal AI Institute for Clinical Herzegovina: Association of Cardiologists of Bosnia and
Translation, Cambridge, United Kingdom; Ian M. Graham, Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of
Department of Cardiology, Trinity College, Dublin, Ireland; Ulf Cardiology, Arman Postadzhiyan; Cyprus: Cyprus Society
Landmesser, Department of Cardiology, Angiology and Intensive of Cardiology, Hera Heracleous; Czechia: Czech Society of
Care Medicine, Deutsches Herzzentrum der Charité, Campus Cardiology, Petr Ostadal; Denmark: Danish Society of Cardiology,
Benjamin Franklin, Berlin, Germany and Friede Springer Cardiovascular Finn Lund Henriksen; Egypt: Egyptian Society of Cardiology,
Prevention Center@Charité, Charité Universitätsmedizin Berlin, Berlin, Mohamed Seleem Mohamed; Estonia: Estonian Society of
Germany; Ulrich Laufs, Department of Cardiology, Leipzig Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society,
University, Leipzig, Germany; Borislava Mihaylova, Wolfson Markus Juonala; France: French Society of Cardiology, Franck
Institute of Population Health, Queen Mary University of London, Boccara; Georgia: Georgian Society of Cardiology, Archil
London, United Kingdom, and Nuffield Department of Population Chukhrukidze; Germany: German Cardiac Society, Oliver
Health, University of Oxford, Oxford, United Kingdom; Børge Weingärtner; Greece: Hellenic Society of Cardiology, Maria
Grønne Nordestgaard, Clinical Biochemistry, Copenhagen Marketou; Hungary: Hungarian Society of Cardiology, Robert
University Hospital - Herlev and Gentofte, Copenhagen, Denmark and Gabor Kiss; Iceland: Icelandic Society of Cardiology, Axel
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, F. Sigurdsson; Ireland: Irish Cardiac Society, Vincent Maher;
5202SAE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 17 ---
ESC Guidelines 4375
Israel: Israel Heart Society, Yaakov Henkin; Italy: Italian Federation of 2.SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk
Cardiology, Savina Nodari; Kazakhstan: Association of Cardiologists prediction algorithms: new models to estimate 10-year risk of cardiovascular disease
in Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309
of Kazakhstan, Makhabbat Bekbossynova; Kosovo (Republic of):
3.SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk
Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan: prediction algorithms: estimating incident cardiovascular event risk in older persons in
Kyrgyz Society of Cardiology, Erkin Mirrakhimov; Latvia: Latvian four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/10.1093/
Society of Cardiology, Sanda Jegere; Lebanon: Lebanese Society of eurheartj/ehab312
4.Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic
Cardiology, Samir Arnaout; Libya: Libyan Cardiac Society, Osama
acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;
Bheleel; Lithuania: Lithuanian Society of Cardiology, Jurgita Plisiene; 388:1353–64. https://doi.org/10.1056/NEJMoa2215024
Luxembourg: Luxembourg Society of Cardiology, Laurent Visser; 5.Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al.
Malta: Maltese Cardiac Society, Mark Abela; Moldova (Republic Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383:
711–20. https://doi.org/10.1056/NEJMoa2004215
of): Moldavian Society of Cardiology, Victoria Ivanov; Montenegro:
6.Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al.
Montenegro Society of Cardiology, Aneta Boskovic; Morocco: Volanesorsen and triglyceride levels in Familial Chylomicronemia syndrome. N Engl J
Moroccan Society of Cardiology, Nazzi Mbarek; Netherlands: Med 2019;381:531–42. https://doi.org/10.1056/NEJMoa1715944
Netherlands Society of Cardiology, Maarten J.G. Leening; North 7.Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al.
Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 2023;
Macedonia: National Society of Cardiology of North Macedonia,
389:687–99. https://doi.org/10.1056/NEJMoa2304146
Marijan Bosevski; Norway: Norwegian Society of Cardiology, 8.Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-
Elisabeth K. Vesterbekkmo; Poland: Polish Cardiac Society, Jacek dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients
Kubica; Portugal: Portuguese Society of Cardiology, Jorge Ferreira; at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:
2268–80. https://doi.org/10.1001/jama.2020.22258 Romania: Romanian Society of Cardiology, Dana Pop; San Marino:
9.Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al.
San Marino Society of Cardiology, Umberto Maria Stefanelli; Serbia: Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA rando-
Cardiology Society of Serbia, Vojislav Giga; Slovakia: Slovak Society mized clinical trial. JAMA 2023;330:528–36. https://doi.org/10.1001/jama.2023.11887
of Cardiology, Daniel Pella; Slovenia: Slovenian Society of 10.Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al.
Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, Rosa
lipids and inflammatory biomarkers. J Am Coll Cardiol 2023;81:1–12. https://doi.org/
Fernandez-Olmo; Sweden: Swedish Society of Cardiology, Lennart 10.1016/j.jacc.2022.10.013
Nilsson; Switzerland: Swiss Society of Cardiology, Isabella Sudano; 11.Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty
Syrian Arab Republic: Syrian Cardiovascular Association, acid supplements in elderly patients after myocardial infarction: a randomized, controlled
trial. Circulation 2021;143:528–39. https://doi.org/10.1161/CIRCULATIONAHA.120.
Mohamed Yassin Bani Marjeh; Tunisia: Tunisian Society of
052209
Cardiology and Cardiovascular Surgery, Faten Triki; Türkiye: Turkish 12.Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al.
Society of Cardiology, Muzaffer M. Degertekin; Ukraine: Ukrainian Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence
Association of Cardiology, Olena Mitchenko; United Kingdom of from genetic, epidemiologic, and clinical studies. A consensus statement from the
European Atherosclerosis Society Consensus panel. Eur Heart J 2017;38:2459–72.
Great Britain and Northern Ireland: British Cardiovascular
https://doi.org/10.1093/eurheartj/ehx144
Society, Amitava Banerjee; and Uzbekistan: Association of 13.Cholesterol Treatment Trialists Collaboration; Baigent C, Blackwell L, Emberson J,
Cardiologists of Uzbekistan, Aleksandr Shek. Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL chol-
ESC Clinical Practice Guidelines (CPG) Committee: Ulf esterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet 2010;376:1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5
Landmesser (Chairperson) (Germany), Stefan James
14.Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P,
(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood
(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin pressure: a meta-analysis of individual data from 61 prospective studies with
Baigent (United Kingdom), Michael A. Borger (Germany), Giuseppe 55,000 vascular deaths. Lancet 2007;370:1829–39. https://doi.org/10.1016/S0140-
6736(07)61778-4
Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland),
15.Mendieta G, Pocock S, Mass V, Moreno A, Owen R, Garcia-Lunar I, et al. Determinants
Estelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll
Hennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United Cardiol 2023;82:2069–83. https://doi.org/10.1016/j.jacc.2023.09.814
16.Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of
Kingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy
evolocumab on acute arterial events across all vascular territories: results from
(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard the FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/
(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), ehab604
Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino 17.Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; (Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski
42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
(Poland), and Katja Zeppenfeld (Netherlands).
18.van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ,
EAS Executive Committee: Børge Grønne Nordestgaard Visseren FLJ, et al. Validation of systematic coronary risk evaluation 2 (SCORE2)
(President) (Denmark), Shoaib Afzal (Denmark), Marianne Benn and SCORE2-older persons in the EPIC-Norfolk prospective population cohort. Eur
J Prev Cardiol 2024;31:182–9. https://doi.org/10.1093/eurjpc/zwad318
(Denmark), Kirsten B. Holven (Norway), Meral Kayikcioglu (Türkiye),
19.Fernandez-Friera L, Garcia-Alvarez A, Oliva B, Garcia-Lunar I, Garcia I,
Ulrich Laufs (Germany), Evangelos Liberopoulos (Greece), Katariina
Moreno-Arciniegas A, et al. Association between subclinical atherosclerosis burden
Öörni (Finland), Kausik K. Ray (United Kingdom), and Jeanine and unrecognized myocardial infarction detected by cardiac magnetic resonance in
Roeters van Lennep (Netherlands). middle-aged low-risk adults. Eur Heart J Cardiovasc Imaging 2024;25:968–75. https://
doi.org/10.1093/ehjci/jeae044
20.Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk
factors in cardiovascular disease risk assessment: updated evidence report and system-
15. References atic review for the US Preventive Services Task Force. JAMA 2018;320:281–97. https://
doi.org/10.1001/jama.2018.4242
1.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ 21.Dzaye O, Razavi AC, Michos ED, Mortensen MB, Dardari ZA, Nasir K, et al. Coronary
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce artery calcium scores indicating secondary prevention level risk: findings from the CAC
cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ consortium and FOURIER trial. Atherosclerosis 2022;347:70–6. https://doi.org/10.
ehz455 1016/j.atherosclerosis.2022.02.006
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 18 ---
4376 E S C G u id e l in e s
22.Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year 42.Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and
association of coronary artery calcium with atherosclerotic cardiovascular disease efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:
(ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J 1022–32. https://doi.org/10.1056/NEJMoa1803917
2018;39:2401–8. https://doi.org/10.1093/eurheartj/ehy217 43.Bays HE, Baum SJ, Brinton EA, Plutzky J, Hanselman JC, Teng R, et al. Effect of bempe-
23.Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo MS, et al. Predictive value of doic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-
coronary artery calcium score categories for coronary events versus strokes: impact of density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterol-
sex and race: MESA and DHS. Circ Cardiovasc Imaging 2020;13:e010153. https://doi. emia not treated with statins. Am J Prev Cardiol 2021;8:100278. https://doi.org/10.1016/
org/10.1161/CIRCIMAGING.119.010153 j.ajpc.2021.100278
24.Peng AW, Dardari ZA, Blumenthal RS, Dzaye O, Obisesan OH, Iftekhar Uddin SM, 44.Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic
et al. Very high coronary artery calcium (≥1000) and association with cardiovascular acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia
disease events, non-cardiovascular disease outcomes, and mortality: results from and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol
2020;27:593–603. https://doi.org/10.1177/2047487319864671
MESA. Circulation 2021;143:1571–83. https://doi.org/10.1161/CIRCULATIONAHA.
45.Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of
120.050545
bempedoic acid among patients with and without diabetes: prespecified analysis of the
25.Peng AW, Mirbolouk M, Orimoloye OA, Osei AD, Dardari Z, Dzaye O, et al.
CLEAR outcomes randomised trial. Lancet Diabetes Endocrinol 2024;12:19–28. https://
Long-term all-cause and cause-specific mortality in asymptomatic patients with
doi.org/10.1016/S2213-8587(23)00316-9
CAC ≥1,000: results from the CAC Consortium. JACC Cardiovasc Imaging 2020;13:
46.Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
83–93. https://doi.org/10.1016/j.jcmg.2019.02.005
randomization study of ACLY and cardiovascular disease. N Engl J Med 2019;380:
26.Valenti V, Ó Hartaigh B, Heo R, Cho I, Schulman-Marcus J, Gransar H, et al. A 15-year
1033–42. https://doi.org/10.1056/NEJMoa1806747
warranty period for asymptomatic individuals without coronary artery calcium: a pro-
47.Lincoff AM, Ray KK, Sasiela WJ, Haddad T, Nicholls SJ, Li N, et al. Comparative cardio-
spective follow-up of 9,715 individuals. JACC Cardiovasc Imaging 2015;8:900–9. https://
vascular benefits of bempedoic acid and statin drugs. J Am Coll Cardiol 2024;84:152–62.
doi.org/10.1016/j.jcmg.2015.01.025
https://doi.org/10.1016/j.jacc.2024.04.048
27.Hageman SHJ, Petitjaen C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, et al.
48.Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible
Inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507–19.
addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol 2023;30:1705–14.
https://doi.org/10.1056/NEJMoa1912387
https://doi.org/10.1093/eurjpc/zwad187 49.Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on
28.Fuchs A, Kuhl JT, Sigvardsen PE, Afzal S, Knudsen AD, Moller MB, et al. Subclinical cor- European Atherosclerosis Society Consensus statement on homozygous familial
onary atherosclerosis and risk for myocardial infarction in a Danish cohort: a prospect- hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J 2023;44:
ive observational cohort study. Ann Intern Med 2023;176:433–42. https://doi.org/10. 2277–91. https://doi.org/10.1093/eurheartj/ehad197
7326/M22-3027 50.Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al.
29.Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, et al. Effects of statins on coronary Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and effi-
atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging 2018;11: cacy. Eur Heart J 2024;45:2422–34. https://doi.org/10.1093/eurheartj/ehae325
1475–84. https://doi.org/10.1016/j.jcmg.2018.04.015 51.Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al.
30.van Rosendael AR, van den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia.
Association of statin treatment with progression of coronary atherosclerotic plaque Circulation 2024;149:343–53. https://doi.org/10.1161/CIRCULATIONAHA.123.065529
composition. JAMA Cardiol 2021;6:1257–66. https://doi.org/10.1001/jamacardio.2021. 52.Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe
3055 lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or
31.Marx N, Federici M, Schütt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140:
Guidelines for the management of cardiovascular disease in patients with diabetes. Eur 992–1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415
Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192 53.Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy
32.SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin in-
SCORE2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in tolerance: the GAUSS-3 randomized clinical trial. JAMA 2016;315:1580–90. https://
Europe. Eur Heart J 2023;44:2544–56. https://doi.org/10.1093/eurheartj/ehad260 doi.org/10.1001/jama.2016.3608
33.Mortensen MB, Tybjaerg-Hansen A, Nordestgaard BG. Statin eligibility for primary 54.Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al.
prevention of cardiovascular disease according to 2021 European Prevention Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin
Guidelines compared with other international guidelines. JAMA Cardiol 2022;7: rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:
836–43. https://doi.org/10.1001/jamacardio.2022.1876 758–69. https://doi.org/10.1016/j.jacl.2015.08.006
34.Domanski MJ, Wu CO, Tian X, Hasan AA, Ma X, Huang Y, et al. Association of incident 55.Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect
cardiovascular disease with time course and cumulative exposure to multiple risk fac- of bempedoic acid vs placebo added to maximally tolerated statins on low-density
lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR
tors. J Am Coll Cardiol 2023;81:1151–61. https://doi.org/10.1016/j.jacc.2023.01.024
35.Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. wisdom randomized clinical trial. JAMA 2019;322:1780–8. https://doi.org/10.1001/
jama.2019.16585 Association of genetic variants related to combined exposure to lower low-density li-
56.de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early inten- poproteins and lower systolic blood pressure with lifetime risk of cardiovascular dis-
sive vs a delayed conservative simvastatin strategy in patients with acute coronary syn-
ease. JAMA 2019;322:1381–91. https://doi.org/10.1001/jama.2019.14120
dromes: phase Z of the A to Z trial. JAMA 2004;292:1307–16. https://doi.org/10.1001/
36.Fuster V, Garcia-Alvarez A, Devesa A, Mass V, Owen R, Quesada A, et al. Influence of
jama.292.11.1307
subclinical atherosclerosis burden and progression on mortality. J Am Coll Cardiol 2024;
57.Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late
84:1391–403. https://doi.org/10.1016/j.jacc.2024.06.045
benefits of high-dose atorvastatin in patients with acute coronary syndromes: results
37.Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (lipopro-
from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–10. https://doi.org/
tein[a]) concentrations and incident atherosclerotic cardiovascular disease: new in-
10.1016/j.jacc.2005.03.077
sights from a large national biobank. Arterioscler Thromb Vasc Biol 2021;41:465–74.
58.Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC
https://doi.org/10.1161/ATVBAHA.120.315291
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:
38.Cholesterol Treatment Trialists Collaboration; Fulcher J, O’Connell R, Voysey M,
3720–826. https://doi.org/10.1093/eurheartj/ehad191
Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men
59.Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC
and women: meta-analysis of individual data from 174,000 participants in 27 randomised Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;
trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4 45:3415–537. https://doi.org/10.1093/eurheartj/ehae177
39.Cholesterol Treatment Trialists Collaborators; Mihaylova B, Emberson J, Blackwell L, 60.Rossello X, Bueno H, Pocock SJ, Van de Werf F, Danchin N, Annemans L, et al.
Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in Predictors of all-cause mortality and ischemic events within and beyond 1 year after
people at low risk of vascular disease: meta-analysis of individual data from 27 rando- an acute coronary syndrome: results from the EPICOR registry. Clin Cardiol 2019;
mised trials. Lancet 2012;380:581–90. https://doi.org/10.1016/S0140-6736(12)60367-5 42:111–9. https://doi.org/10.1002/clc.23116
40.Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and 61.Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular
when. Curr Atheroscler Rep 2022;24:791–801. https://doi.org/10.1007/s11883-022- risk in post-myocardial infarction patients: nationwide real world data demonstrate
01054-2 the importance of a long-term perspective. Eur Heart J 2015;36:1163–70. https://
41.Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific doi.org/10.1093/eurheartj/ehu505
ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates ath- 62.Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event rates and risk factors for
erosclerosis. Nat Commun 2016;7:13457. https://doi.org/10.1038/ncomms13457 recurrent cardiovascular events and mortality in a contemporary post acute coronary
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 19 ---
ESC Guidelines 4377
syndrome population representing 239 234 patients during 2005 to 2018 in the B-containing lipoproteins. J Am Coll Cardiol 2024;83:470–2. https://doi.org/10.1016/j.
United States. J Am Heart Assoc 2022;11:e022198. https://doi.org/10.1161/JAHA.121. jacc.2023.09.836
022198 82.Welsh P, Welsh C, Celis-Morales CA, Brown R, Ho FK, Ferguson LD, et al.
63.Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and es-
lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients timating benefits from novel interventions. Eur J Prev Cardiol 2022;28:1991–2000.
and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 2021;42: https://doi.org/10.1093/eurjpc/zwaa063
243–52. https://doi.org/10.1093/eurheartj/ehaa1011 83.Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet 2024;
64.De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L, et al. 404:1255–64. https://doi.org/10.1016/S0140-6736(24)01308-4
Management of dyslipidaemia in patients with coronary heart disease: results from 84.Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels
the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285: and improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146–56.
135–46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014 https://doi.org/10.1016/j.jacc.2012.12.023
65.Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross- 85.Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ische-
sectional observational study of lipid-modifying therapy use in secondary and primary mic stroke. J Am Coll Cardiol 2019;74:54–66. https://doi.org/10.1016/j.jacc.2019.03.524
care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279–89. https://doi.org/10.1093/ 86.Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et al. Independent associ-
eurjpc/zwaa047 ation of lipoprotein(a) and coronary artery calcification with atherosclerotic cardio-
66.Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. vascular risk. J Am Coll Cardiol 2022;79:757–68. https://doi.org/10.1016/j.jacc.2021.11.
Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 058
2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489 87.Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al.
67.Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in pa-
Evolocumab for early reduction of LDL cholesterol levels in patients with acute cor- tients with atherosclerotic cardiovascular disease. J Am Coll Cardiol 2022;80:
onary syndromes (EVOPACS). J Am Coll Cardiol 2019;74:2452–62. https://doi.org/10. 1998–2010. https://doi.org/10.1016/j.jacc.2022.09.021
1016/j.jacc.2019.08.010 88.Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked
68.Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur
evolocumab on atherogenic lipoproteins during the peri- and early postinfarction per- Heart J 2023;44:1449–60. https://doi.org/10.1093/eurheartj/ehad055
iod: a placebo-controlled, randomized trial. Circulation 2020;142:419–21. https://doi. 89.Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR.
org/10.1161/CIRCULATIONAHA.120.046320 Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm,
69.Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling JA, Romer R, et al. and major adverse limb events. J Am Coll Cardiol 2023;82:2265–76. https://doi.org/
Intensive lipid-lowering therapy for early achievement of guideline-recommended 10.1016/j.jacc.2023.10.009
LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf 90.Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG,
Ziel”). Clin Res Cardiol 2023;112:1212–9. https://doi.org/10.1007/s00392-022-02147-3 G Kees Hovingh, et al. Low-density lipoprotein cholesterol, C-reactive protein, and li-
70.Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolo- poprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk
cumab on coronary plaque phenotype and burden in statin-treated patients following study. Eur Heart J 2025;46:3875–84. https://doi.org/10.1093/eurheartj/ehaf209
myocardial infarction. JACC Cardiovasc Imaging 2022;15:1308–21. https://doi.org/10. 91.Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex
1016/j.jcmg.2022.03.002 differences of lipoprotein(a) levels and associated risk of morbidity and mortality by
71.Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, et al. Effect of alirocumab age: the Copenhagen general population study. Atherosclerosis 2022;355:76–82.
added to high-intensity statin therapy on coronary atherosclerosis in patients with https://doi.org/10.1016/j.atherosclerosis.2022.06.1023
acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 92.de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al.
327:1771–81. https://doi.org/10.1001/jama.2022.5218 Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J
72.Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al. Clinical Prev Cardiol 2022;29:779–92. https://doi.org/10.1093/eurjpc/zwab171
efficacy and safety of alirocumab after acute coronary syndrome according to achieved 93.Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and
level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: indi-
ODYSSEY OUTCOMES trial. Circulation 2021;143:1109–22. https://doi.org/10.1161/ vidual patient-data meta-analysis of statin outcome trials. Lancet 2018;392:1311–20.
CIRCULATIONAHA.120.049447 https://doi.org/10.1016/S0140-6736(18)31652-0
73.Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical 94.Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ,
efficacy and safety of achieving very low LDL-cholesterol concentrations with the Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular
PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. disease. N Engl J Med 2020;382:244–55. https://doi.org/10.1056/NEJMoa1905239
Lancet 2017;390:1962–71. https://doi.org/10.1016/S0140-6736(17)32290-0 95.O’Donoghue ML, Rosenson RS, Gencer B, Lopez JAG, Lepor NE, Baum SJ, et al. Small
74.Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Bujas-Bobanovic M, Diaz R, et al. interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022;
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after 387:1855–64. https://doi.org/10.1056/NEJMoa2211023
acute coronary syndrome are associated with cardiovascular risk reduction: the 96.Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single
ODYSSEY OUTCOMES trial. Eur Heart J 2023;44:1408–17. https://doi.org/10.1093/ ascending dose study of a short interfering RNA targeting lipoprotein(a) production in
eurheartj/ehad144 individuals with elevated plasma lipoprotein(a) levels. JAMA 2022;327:1679–87. https://
75.Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, et al. Intensive doi.org/10.1001/jama.2022.5050
early and sustained lowering of non-high-density lipoprotein cholesterol after myocar- 97.Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an
dial infarction and prognosis: the SWEDEHEART registry. Eur Heart J 2024;45: extended-duration short interfering RNA targeting lipoprotein(a): a randomized
4204–15. https://doi.org/10.1093/eurheartj/ehae576 dose-ascending clinical trial. JAMA 2023;330:2075–83. https://doi.org/10.1001/jama.
76.Leosdottir M, Hagstrom E, Hadziosmanovic N, Norhammar A, Lindahl B, Hambraeus 2023.21835
K, et al. Temporal trends in cardiovascular risk factors, lifestyle and secondary prevent- 98.Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral
ive medication for patients with myocardial infarction attending cardiac rehabilitation small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial.
in Sweden 2006–2019: a registry-based cohort study. BMJ Open 2023;13:e069770. JAMA 2023;330:1042–53. https://doi.org/10.1001/jama.2023.16503
https://doi.org/10.1136/bmjopen-2022-069770 99.Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin
77.Allahyari A, Jernberg T, Hagstrom E, Leosdottir M, Lundman P, Ueda P. Application of for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:222–31.
the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a re- https://doi.org/10.1001/jama.2024.24017
cent myocardial infarction: a simulation study. Eur Heart J 2020;41:3900–9. https:// 100. Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-a
doi.org/10.1093/eurheartj/ehaa034 small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA
78.Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. 2024;332:1992–2002. https://doi.org/10.1001/jama.2024.21957
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a 101. Berman AN, Biery DW, Besser SA, Singh A, Shiyovich A, Weber BN, et al.
European Atherosclerosis Society Consensus Statement. Eur Heart J 2022;43: Lipoprotein(a) and major adverse cardiovascular events in patients with or without
3925–46. https://doi.org/10.1093/eurheartj/ehac361 baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol 2024;83:873–86.
79.Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mor- https://doi.org/10.1016/j.jacc.2023.12.031
tality. Eur Heart J 2019;40:2760–70. https://doi.org/10.1093/eurheartj/ehy902 102. Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant choles-
80.Bjornson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, et al. terol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur
Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based gen- Heart J 2023;44:1432–45. https://doi.org/10.1093/eurheartj/ehac822
etic analysis. J Am Coll Cardiol 2024;83:385–95. https://doi.org/10.1016/j.jacc.2023.10.039 103. Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated
81.Marston NA, Melloni GEM, Murphy SA, Morze J, Kamanu FK, Ellinor PT, et al. LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136–52. https://
Per-particle cardiovascular risk of lipoprotein(a) vs non-Lp(a) apolipoprotein doi.org/10.1016/j.jacc.2022.10.019
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
--- Страница 20 ---
4378 E S C G u id e l in e s
104. Raposeiras-Roubin S, Rossello X, Oliva B, Fernandez-Friera L, Mendiguren JM, Andres 123. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new in-
V, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021;77: sights into pathogenesis and clinical manifestations in a global context. Circulation 2023;
3031–41. https://doi.org/10.1016/j.jacc.2021.04.059 147:83–100. https://doi.org/10.1161/CIRCULATIONAHA.122.057443
105. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovas- 124. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular
cular disease and stroke. Cochrane Database Syst Rev 2015;2015:CD009580. https:// risk prediction functions underestimate risk in HIV infection. Circulation 2018;137:
doi.org/10.1002/14651858.CD009580.pub2 2203–14. https://doi.org/10.1161/CIRCULATIONAHA.117.028975
106. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, et al. Effects of 125. Kentoffio K, Temu TM, Shakil SS, Zanni MV, Longenecker CT. Cardiovascular disease
combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–74. risk in women living with HIV. Curr Opin HIV AIDS 2022;17:270–8. https://doi.org/10.
https://doi.org/10.1056/NEJMoa1001282 1097/COH.0000000000000756
107. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term 126. University of Liverpool. HIV Drug Interactions. https://www.hiv-druginteractions.org/
fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mel- (27 July 2024, date last accessed).
litus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61. https:// 127. Negredo E, Molto J, Puig J, Cinquegrana D, Bonjoch A, Perez-Alvarez N, et al.
doi.org/10.1016/S0140-6736(05)67667-2
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in
108. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, et al. Effect of fenofi-
HIV-infected patients with poor response to statins. AIDS 2006;20:2159–64. https://
brate on amputation events in people with type 2 diabetes mellitus (FIELD study): a
doi.org/10.1097/01.aids.0000247573.95880.db
prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780–8.
128. Chow D, Chen H, Glesby MJ, Busti A, Souza S, Andersen J, et al. Short-term ezetimibe
https://doi.org/10.1016/S0140-6736(09)60698-X
is well tolerated and effective in combination with statin therapy to treat elevated LDL
109. Pradhan AD, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al.
cholesterol in HIV-infected patients. AIDS 2009;23:2133–41. https://doi.org/10.1097/
Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med
QAD.0b013e32833068e3
2022;387:1923–34. https://doi.org/10.1056/NEJMoa2210645
129. Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of
110. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC
ezetimibe combined with rosuvastatin compared with titrating rosuvastatin mono- Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J
2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179 therapy in HIV-positive patients. Lipids Health Dis 2015;14:57. https://doi.org/10.
111. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. 1186/s12944-015-0054-x
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J 130. Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, et al. Evolocumab in
Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792 HIV-infected patients with dyslipidemia: primary results of the randomized, double-
112. Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT Jr, et al. Mineral oil: safety blind BEIJERINCK study. J Am Coll Cardiol 2020;75:2570–84. https://doi.org/10.1016/
and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020; j.jacc.2020.03.025
22(Suppl J):J34–48. https://doi.org/10.1093/eurheartj/suaa117 131. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late car-
113. Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, et al. Effects of randomized diomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:
treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, 1864–71. https://doi.org/10.1200/JCO.2004.06.033
interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, 132. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing
homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized,
REDUCE-IT biomarker substudy. Circulation 2022;146:372–9. https://doi.org/10. single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233–41.
1161/CIRCULATIONAHA.122.059410 https://doi.org/10.1177/1074248418821721
114. U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. 133. Hundley WG, D’Agostino R Jr, Crotts T, Craver K, Hackney MH, Jordan JH, et al.
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey= Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM
480815(22 October 2024, date last accessed). Evid 2022;1:10. https://doi.org/10.1056/EVIDoa2200097
115. Sherratt SCR, Libby P, Dawoud H, Bhatt DL, Mason RP. Eicosapentaenoic acid im- 134. Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins
proves endothelial nitric oxide bioavailability via changes in protein expression during to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk
inflammation. J Am Heart Assoc 2024;13:e034076. https://doi.org/10.1161/JAHA.123. receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 2023;9:515–25. https://
034076 doi.org/10.1093/ehjcvp/pvad031
116. Sherratt SCR, Libby P, Bhatt DL, Mason RP. A biological rationale for the disparate ef- 135. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.
fects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot
2022 ESC Guidelines on cardio-oncology developed in collaboration with the
Essent Fatty Acids 2022;182:102450. https://doi.org/10.1016/j.plefa.2022.102450
European Hematology Association (EHA), the European Society for Therapeutic
117. Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS,
Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society
Gouni-Berthold I, et al. Volanesorsen to prevent acute pancreatitis in hypertriglycer-
(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
idemia. N Engl J Med 2024;390:476–7. https://doi.org/10.1056/NEJMc2306575
136. D’Amario D, Laborante R, Bianchini E, Galli M, Ciliberti G, Mennuni M, et al. Statins as
118. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al.
preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized
Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med
controlled trials. Int J Cardiol 2023;391:131219. https://doi.org/10.1016/j.ijcard.2023.
2024;390:1770–80. https://doi.org/10.1056/NEJMoa2402309
131219
119. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne
137. Felix N, Nogueira PC, Silva IM, Costa TA, Campello CA, Stecca C, et al.
CM, et al. Olezarsen, acute pancreatitis, and Familial Chylomicronemia syndrome. N
Engl J Med 2024;390:1781–92. https://doi.org/10.1056/NEJMoa2400201 Cardio-protective effects of statins in patients undergoing anthracycline-based chemo-
120. Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran therapy: an updated meta-analysis of randomized controlled trials. Eur J Intern Med
for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med 2025;392: 2024;126:43–8. https://doi.org/10.1016/j.ejim.2024.04.007
127–37. https://doi.org/10.1056/NEJMoa2409368 138. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, et al.
121. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an Continuous dose-response relationship of the LDL-cholesterol-lowering effect of
RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med phytosterol intake. J Nutr 2009;139:271–84. https://doi.org/10.3945/jn.108.095125
2024;391:899–912. https://doi.org/10.1056/NEJMoa2404143 139. The European Commission. Commission Regulation (EU) 2022/860 of 1 June 2022
122. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atheroscler- Amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and
otic cardiovascular disease in people living with HIV: systematic review and meta-analysis. of the Council as Regards Monacolins From Red Yeast Rice. https://eur-lex.europa.eu/
Circulation 2018;138:1100–12. https://doi.org/10.1161/CIRCULATIONAHA.117.033369 eli/reg/2022/860/oj(17 August 2024, date last accessed).
Downloaded
from
https://academic.oup.com/eurheartj/article/46/42/4359/8234482
by
guest
on
22
January
2026
